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1 Introduction
Under the Medicare Part D prescription drug benefit, private insurers offer a wide range
of products with varying prices and features. While the government sets a standard
insurance design, over 90% of enrollees are enrolled in non-standard plans, subject to
the constraint that these alternatives be at least as generous as the standard plan.
In particular, insurance plans offered through Medicare Part D vary widely in their
deductibles, in the copayments and coinsurance for prescriptions above the deductible,
and in their coverage of drugs in the infamous Part D “donut hole” where the standard
plan offers no coverage. A number of analysts have expressed concern both about the
overall generosity of the standard package, and about consumer confusion in choosing
across this wide variety of alternatives. Responding to the former concern, the Patient
Protection and Affordable Care Act (ACA) of 2010 “fills in” the donut hole for the
standard plan design.
The welfare impacts of these variations in plan design, as well as of filling in the donut
hole in the future, depend critically on how prescription drug spending responds to Part
D coverage. But the complex nature of Part D contracts makes it difficult to correctly
model the effects of Part D coverage on drug spending. Enrollees face a complicated
non-linear budget constraint for their drug consumption decisions, whereby both current
and future prices for drugs are a function of consumption to date, as well as a dynamic
environment in which uncertainty is realized gradually over time. The complexity of this
optimization problem may be particularly onerous for the elderly Part D population.
In this paper, we present a model of prescription drug coverage under Part D which
accounts for optimization with non-linear budget sets, dynamic incentives due to un-
certainty and myopia, and variation in salience of different aspects of the insurance
contract. The standard approaches to estimating demand in the presence of non-linear
budget sets are either to estimate a nonlinear structural model assuming a particular
model of optimization behavior as in Hausman (1985) and Kowalski (2013); or to esti-
mate a nonparametric model with higher order terms for each segment and threshold
of the budget set as in Blomquist and Newey (2002). The nonparametric approach has
the advantage of flexibility and requires fewer assumptions, but places substantial de-
mands on the data to achieve identification (making its application infeasible in the Part
D context). Moreover, traditional models of a structural response to nonlinear budget
sets assume that all price responses reflect a single price elasticity. More recent exam-
ples relax this assumption to incorporate behavioral responses such as myopia, typically
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modeled using a discount factor; see Einav, Finkelstein, and Schrimpf (2014) and Dal-
ton, Gowrisankaran, and Town (2015) for two excellent recent examples in the Part D
context.
We add to these literatures by combining positive aspects of both. We propose a
method of estimating structural models of behavior, which enables simulation of con-
sumption under counterfactual price schedules. In a similar spirit to Blomquist and
Newey, we use estimation methods that relax two key limitations in typical structural
models. First, as has been discussed in detail in the energy economics literature, lack of
information or understanding about prices may lead consumers in nonlinear contracts
(such as insurance contracts and electricity contracts) to use rules of thumb beyond
discounting in determining their consumption. For example, Liebman and Zeckhauser
(2004) note that individuals may respond to nonlinear price schedules by “ironing”
(responding to average or local average prices), or by “spotlighting” (responding to im-
mediate “spot” prices rather than to future marginal prices). The latter behavior can
be captured in a structural model with discounting; the former can not. Second, just
as consumers may not be perfectly forward-looking in their consumption behavior, they
may also be confused about how visible changes in benefit coverage impact the prices
they face. A large recent literature in economics highlights the role of price salience,
which leads consumers in complex or opaque environments to be inattentive to some
prices (see Chetty, Looney, and Kroft (2009) for a review). The structural empirical
literature in health care has not typically allowed for consumer responses to vary with
price salience.
We demonstrate that linear regression methods can be used to recover parameters
from structural models of consumption for individuals whose marginal prices are in the
interiors of budget set segments, and these parameters can in turn be used to forecast
nonlinear consumption behavior (e.g., at kink points). The simplicity of our model
and our identification strategy based on variation in prices at multiple points in the
budget set allow us to be quite flexible in modeling how consumers respond to different
coverage range prices at different times. We employ a simplified version of Blomquist
and Newey by considering the linear response to budget set segment prices (there is no
meaningful cross-sectional variation in threshold locations); we also allow enrollees to
respond to variables capturing nominally large changes in benefit coverage that may be
more salient. We limit the potential for bias by restricting our sample to individuals
who are extremely likely to end the year well in the interior of a budget set segment.
We can then examine performance of structural models with more restrictive models of
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expectations. In this setting, the model in which enrollees respond myopically to current
and expected future prices as well as price salience terms fits the data quite well both
in and outside the regression sample.
The main data source is a 20% sample of Medicare Part D claims provided by the
Centers for Medicare and Medicaid Services (CMS). This claims data include information
on drugs consumed, as well as the date, quantity, wholesale price and amount paid by
insurer and beneficiary for each claim. Our identification strategy utilizes the substantial
inertia in plan choice present in the Medicare beneficiary population – once an initial plan
has been chosen, the vast majority of enrollees remain in that plan in subsequent years
even though plan cost-sharing characteristics may change substantially. We therefore
analyze how year-to-year changes in cost-sharing features of plans impact changes in the
pattern of prescription drug utilization.1
We begin our analysis with a differences-in-differences regression to illustrate the
thought experiment behind our identification strategy. We regress the change in con-
sumption on the change in donut hole coverage among individuals in plans matched on
all coverage features in the prior year and for which one plan changed donut hole cover-
age in the current year. These reduced form results demonstrate that Part D enrollees’
consumption is sensitive to the presence of donut hole coverage, all else equal, and that
that sensitivity increases throughout the year as more individuals enter the donut hole.
We extend this analysis by estimating reduced form regressions of year-to-year con-
sumption changes on budget segment price changes and changes in salient coverage char-
acteristics. Consumers’ responses to different coverage phase prices vary steeply with
the proportion of enrollees currently in those coverage phases, even holding marginal
coverage phase fixed. In our preferred structural model in which consumers respond to
current and future prices, these patterns reveal consumers’ price elasticities and degree
of myopia. We find overall price elasticities of around -0.13 on average, which is of a sim-
ilar magnitude to the previous literature on prescription drug and health care services
demand. The dynamics in the observed marginal price responses imply an estimated
(quarterly) β (in a β − δ discounting model) of 0.31, suggesting a very high degree
of myopia. We find that our parsimonious “linear” model gives the same results as a
more complete structural model which incorporates nonlinear responses such as bunch-
1We thus consider the consumption response to coverage generosity changes within the set of existing
enrollees – to the extent that price elasticities vary over the range of possible prices or differ based on
the timing of price changes, this may lead us to obtain different estimates than those in the literature
that considers the response of new enrollees when Part D was introduced. See, e.g., Duggan and Scott
Morton (2008).
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ing and coverage range switching. Notably, the preferred structural model we employ for
counterfactual simulations predicts out-of-sample spending better than models in which
consumers respond to marginal price, as would be expected with a rational, forward-
looking individual, or in which they respond to average price, as in rule-of-thumb models
discussed in the energy literature.
We also examine whether individuals respond excessively to particularly salient plan
cost-sharing features – behavioral biases in consumption may impact consumer weighting
of particular coverage characteristics based on visibility, in addition to leading them to
inappropriately weight prices across coverage phases. Empirical studies of taxation have
found evidence of such biases; for example, Feldman, Katuscak, and Kawano (2013)
find that consumers responded to the removal of the lump sum Child Tax Credit by
reducing their labor income, even though the removal did not impact their net wages.
Indeed, we find evidence that plan donut coverage impacts consumption more than
would be expected given its impact on either current or expected marginal price. Our
most striking evidence of salience is that even low-spending individuals who are highly
unlikely to enter the donut hole are nonetheless responsive in their consumption to the
presence or absence of donut hole coverage.
Using the structural parameters implied by our linear estimates, we simulate con-
sumption responses over the entire nonlinear budget set and estimate the consumption
response to the counterfactual of filling in the Part D donut hole. We demonstrate that,
given our estimates, it matters not just what prices are changed, but also when they
change in the year and how the price changes are presented. Filling in the donut hole
will lead to substantial increases in consumption, but such increases will be realized
unevenly over the year and will affect even low-spending parts of the Part D population
due to price salience. Salience effects account for over 30% of the total consumption
response to donut hole coverage.
The rest of the paper proceeds as follows. In Section 2, we describe the background
of the Part D program and the literature on decision-making among the elderly and
moral hazard in health care. Section 3 describes our identification strategy. Section 4
describes the data and provides details on price variable construction. Section 5 presents
our reduced form analysis of the impact of donut hole coverage on consumption. In
Section 6, we lay out and estimate a structural model which estimates how consumption
responds to prices allowing for both myopia and salience in a dynamic setting. Section 7
translates our price coefficients into structural parameters and shows the results of our
counterfactual simulations. Section 8 concludes.
5
2 Background on Medicare Part D, Elder Decision-
Making, and Moral Hazard in the Medical Con-
text
The Part D program passed in 2003, and was implemented in 2006 to provide, for the
first time, subsidized prescription drug insurance for the elderly.2 The most noticeable
innovation of Part D is that this new Medicare benefit is not delivered by the government,
but rather by private insurers under contract with the government. Beneficiaries can
choose from three types of private insurance plans for coverage of their drug expenditures.
The first type are stand-alone plans called Medicare Prescription Drug Plans (PDPs)
(plans that just offer prescription drug benefits). For example, in 2006, there were
1,429 total PDPs offered nationally, with most states offering about forty PDPs. The
second are Medicare Advantage (MA) plans, plans that provide all Medicare benefits,
including prescription drugs, such as HMO, PPO, or private FFS plans. There were
1,314 MA plans nationally in 2006. Finally, beneficiaries could retain their current
employer/union plans, as long as coverage is “creditable” or at least as generous (i.e.
actuarially equivalent) as the standard Part D plan, for which they would receive a
subsidy from the government. We focus on PDP plans so that other health benefits are
held constant.
Under Part D, recipients are entitled to basic coverage of prescription drugs by a plan
with equal or greater actuarial value to the standard Part D plan. The standard plan
for the year 2006 covers: none of the first $250 in drug costs each year; 75% of costs for
the next $2,000 of drug spending (up to $2,250 total); 0% of costs for the next $3,600 of
drug spending (up to $5,100 total – the infamous “donut hole”); and 95% of costs above
$5,100 of drug spending. Coverage thresholds for the standard plan have increased in
each year since first implementation of the program; the standard plan deductible and
donut threshold in 2009, the last year of our sample, were $295 and $2,700, respectively.
The government also placed restrictions on the structure of the formularies that plans
could use to determine which prescription medications they would insure. In practice,
the vast majority of enrollees have chosen plans with non-standard cost-sharing; over
90% of beneficiaries in 2006 were not enrolled in the standard benefit design, but rather
were in plans with low or no deductibles, flat payments for covered drugs following a
2Duggan et al. (2008) provide a detailed overview of the Part D program and many of the economic
issues it raises, so we just provide a brief overview here.
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tiered system, or some form of coverage in the donut hole. The ACA mandates that the
donut hole be “filled in” gradually by 2020. For the 2014 benefit year, enrollees in plans
that do not have coverage in the donut hole are entitled to a 52.5% discount on branded
drugs and a 21% discount on generics while in the donut hole.3
Enrollment in Part D plans was voluntary for Medicare eligible citizens. In order to
mitigate adverse selection, Medicare recipients not signing during the initial enrollment
period in the first year of the program or when they aged into Medicare (and who did
not have other creditable prescription drug coverage) were subject to a financial penalty
if they eventually joined the program.4
Our project builds on several literatures. First, we consider decision-making in a
complex setting by an elderly population. Issues considered in behavioral economics,
such as myopia and salience, may be particularly acute among the elderly given that the
potential for cognitive failures rises at older ages. A recent study by Sumit Agarwal, John
C. Driscoll, Xavier Gabaix, and David Laibson (2006) shows that in ten different con-
texts, ranging from credit card interest payments to mortgages to small business loans,
the elderly pay higher fees and face higher interest rates than middle-aged consumers.5
Several studies of these issues apply specifically to the context of Part D. For example,
Florian Heiss, Daniel McFadden and Joachim Winter (2006); Jeffrey R. Kling, Sendhil
Mullainathan, Eldar Shafir, Lee Vermeulen and Marian V. Wrobel (2008); Abaluck and
Gruber (2011); and Ketcham et al. (2011) each study plan choice under Medicare Part
D and find striking evidence in a variety of empirical settings that elders do not make
cost-minimizing choices of Part D plans (though there is some disagreement regarding
whether choices improved over time). Our project suggests that perhaps the same fea-
tures that lead elders to make errors in financial choices or in choosing the appropriate
Medicare Part D plan lead them also to deviate from rational, forward-looking behavior
in responding to cost-sharing features.
3Drug manufacturers offer the branded discount under the Medicare Coverage Gap Discount Pro-
gram; Medicare covers the 21% generic discount in the donut hole (CMS, 2013).
4One group was automatically enrolled: low income elders who had been receiving their prescription
drug coverage through state Medicaid programs (the “dual eligibles”). These dual eligibles were enrolled
in Part D plans by default if they did not choose one on their own. The Part D plans for dual eligibles
could charge copayments of only $1 for generics/$3 for name brand drugs for those below the poverty
line, and only $2 for generics/$5 for name brand drugs for those above the poverty line, with free coverage
above the out-of-pocket threshold of $3,600. In addition, other low income groups were eligible for the
Low Income Subsidy (LIS) or for other subsidy programs that lowered their premiums and cost sharing.
5See also Timothy A. Salthouse (2004), which shows clear evidence that the performance on a series
of memory and analytic tasks declines sharply after age 60; and Laura Fratiglioni, Diane De Ronchi,
and Hedda A. Torres (1999) for evidence on the relationship between the onset of dementia and age.
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There is also a rich literature on the impact of cost-sharing on health care utiliza-
tion and this literature is reviewed in great detail in Chandra, Gruber, and McKnight
(2008). Of particular note is the RAND Health Insurance Experiment (HIE), which is
summarized in Manning et al. (1987) and Newhouse (1993). The HIE showed that con-
sumption of medical services was modestly price responsive, with an overall estimated
arc-elasticity of medical spending in the range of -0.2.
A large subsequent literature has investigated utilization effects specifically in the
context of prescription drugs. This literature is reviewed in Goldman, Joyce, and Zheng
(2007), which finds elasticities ranging from -0.2 to -0.6. Several studies examine utiliza-
tion effects specifically in the context of Medicare Part D. Lichtenberg and Sun (2007)
examine the change in drug expenditures for elderly and non-elderly consumers follow-
ing the introduction of Part D and estimate that Part D led to a 12.8% increase in
prescription drug utilization (from an 18.4% reduction in patient cost sharing, an arc-
elasticity of -0.70); Yin, et al. (2008) report a 5.9% increase in utilization in data from a
large pharmacy chain. Using different data sources but a similar methodology, Ketcham
and Simon (2007) estimate an arc-elasticity of -0.47. Chandra, Gruber, and McKnight
(2008) analyze another group of retirees, from the California Public Employees Retire-
ment System (CalPERS) and find an arc-elasticity of prescription drug consumption
of -0.08 to -0.15. Thus, previous studies have consistently found evidence that drug
utilization responds to out-of-pocket prices, but the magnitude of the estimates varies
dramatically across studies. Our data include a representative sample of the entire uni-
verse of Medicare Part D claims and will thus shed light on the elasticity of demand for
the full sample of unsubsidized enrollees.
Another literature on healthcare utilization models health care consumption elas-
ticities in the presence of non-standard pricing. Kowalski (2013) studies the aggregate
utilization of medical care in a non-linear budget set environment with a static consump-
tion decision and finds consumers to have quite low price elasticities, thus concluding
that generous coverage leads to modest deadweight losses from moral hazard. Aron-
Dine, Einav, Finkelstein, and Cullen (2014) model dynamic consumption of medical
services in the presence of a varying effective deductible and show that individuals re-
spond not only to their expected marginal price but also to the spot price they face
before reaching coverage thresholds. Einav, Finkelstein, and Schrimpf (2014) consider
Part D enrollees specifically by focusing on dynamic incentives due to enrollees entering
into Part D contracts at different points in the year (as they age into Medicare) and
estimate an overall price elasticity from the degree of bunching observed among individ-
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uals whose total drug expenditures place them near the donut hole threshold at the end
of the year. They estimate a weekly δ of 0.96, which translates roughly to a quarterly β
of 0.5; they find static price elasticities ranging from -0.3 to -0.5. In contrast, Dalton,
Gowrisankaran, and Town (2015) estimate dynamic preferences based on consumption
changes as individuals predictably cross the donut threshold and price elasticities based
on cross-drug substitution as individuals cross the threshold; they find small, but signif-
icant, price elasticities that decline in drug cost, and full myopia (β = 0). Our strategy
builds on this literature to estimate elasticities with respect to variation in both current
and marginal price for a broad range of the overall spending and age distributions.
3 Identification Strategy
The ideal variation to identify the impact of budget sets on consumption would include
independent variation in each segment of the budget set and random assignment of in-
dividuals across plans. Unfortunately for our study as well as all others using Medicare
Part D data, prices are endogenous for several reasons. First, prices result partly from
the consumers’ decision of which plans to choose in light of their expected drug needs –
even in the presence of the potential cognitive failures described above, sicker enrollees
may choose more generous coverage. Second, prices chosen by pharmaceutical compa-
nies rise and fall in response to changes in consumer demand. Third, the non-linear
budget set means that marginal prices mechanically depend on consumption – if the
price increases after the donut hole threshold, we expect to see a mechanical positive re-
lationship between out-of-pocket (OOP) price and consumption, since sicker individuals
are more likely to end up in the donut hole, all else equal.
To deal with the first and second issues, we instrument for prices using variation
generated by changes in Part D plan cost sharing rules and by taking advantage of the
substantial inertia in Part D plan enrollment. The thought experiment that motivates
this strategy is as follows. Consider two elderly individuals, Sheldon and Leonard, who
choose their plans in 2006 and plan to stay in that plan for several years before they
reoptimize. They choose different plans in 2006, but these plans have identical cost-
sharing provisions, and Sheldon and Leonard use identical prescription drugs in 2006.
In 2007, Plan A, in which Sheldon is enrolled, increases its copayments, while Plan B, in
which Leonard is enrolled, does not. Since neither Sheldon nor Leonard is reoptimizing,
there is an exogenous shift in cost sharing between them from 2006 to 2007. That is,
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any difference in spending in 2007 between Sheldon and Leonard is due to cost sharing
changes rather than active plan choices.
Of course, to the extent that we don’t see Sheldon or Leonard switch plans, we can’t
say for certain whether this is because of inertia or because of preferences; it may be that
Sheldon stayed in Plan A not because of a failure to reoptimize, but precisely because
he anticipated having lower prescription drug needs next year, which would lead to
the same endogeneity bias noted above. However, we can compare all individuals who
were in Plan A in 2006 to all individuals who were in Plan B in 2006, conditioning
on any differences in characteristics between these two groups (including differences in
2006 utilization). So long as there is sufficient inertia in plan choice, then, on average,
individuals who were in Plan A in 2006 will see higher copayments in 2007 than those
who were in Plan B in 2006. That is, if some individuals don’t reoptimize for 2007,
there is an exogenous change on average in copayments for the entire group enrolled in
Plan A in 2006. Given the small degree of switching observed in practice (about 10% in
each pair of years in our sample), it seems likely that many individuals are not annually
reoptimizing, a conclusion strongly supported by Abaluck and Gruber (2013).6
The standard approaches to the third problem – non-linear budget sets – are either to
estimate a nonlinear structural model assuming a particular model of optimization be-
havior as in Hausman (1985) or, more recently, Kowalski (2013) and Einav, Finkelstein,
and Schrimpf (2014); or to estimate a nonparametric model with higher order terms for
each segment and threshold of the budget set as in Blomquist and Newey (2002). In
our analyses, we employ a simplified version of Blomquist and Newey by considering
the linear response to budget set segments and by limiting our sample to individuals
who are extremely likely to end the year well in the interior of a budget set segment.
Robustness checks using higher order polynomial terms to isolate individual phase price
responses in a manner analogous to Blomquist-Newey show similar patterns.
Our identification approach has several nice features. First, we have variation in
prices in both the initial coverage phase and donut hole. Over 90% of Medicare Part
D enrollees end the year in one of these two phases, so this allows us to identify a
marginal price response for enrollees over a wide range of total drug expenditures, rather
6The monotonicity constraint required for this instrumental variables strategy to be appropriate
would be violated if, for example, “switchers” respond to coverage generosity decreases in their initially
chosen plan by switching to a more generous plan relative to the initial choice. As noted in the discussion
of our results in Section 6.3, we cannot test the monotonicity assumption directly, but we do note that
our results are not driven primarily by behavior of active switchers – the coefficient estimates are similar
between the full sample and the sample of non-switchers only.
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than focusing on behavior around the convex kink in the budget set at the donut hole
for price variation. Second, variation in both “current” and “future” price as enrollees
spend more over the course of the year allows us to estimate “current” and “future” price
elasticities separately in our dynamic analyses and thus to determine whether consumers
are primarily forward-looking or primarily myopic. Aron-Dine, et al. (2014) separately
identify myopia and static price elasticities by comparing their future price elasticity
estimates with price elasticity estimates calibrated from the RAND experiment; our
variation allows us to make this comparison without relying on any external calibrations.
4 Data and Variable Construction
We analyze data from a 20% sample of Part D enrollees from 2006 through 2009. The
claims data contain information on drugs consumed, date of claim, quantity consumed
(measured in days’ supply purchased on the claim – this is our outcome variable in
all specifications), total retail price, and out-of-pocket price for each individual claim.
The beneficiary data contain demographic variables and enrollment details. The plan
and tier files contain detailed information on drug coverage in each coverage phase as
well as nonlinear threshold information. In order to control as richly as possible for
heterogeneity across individuals, we merge the Part D data with data on health care
utilization in Medicare Parts A and B as well.
For our main analyses, we exclude individuals under 65, individuals who ever received
low-income subsidies (and who thus were not subject to the majority of cost-sharing
variation), and individuals who were enrolled in employer-sponsored plans. We focus on
enrollees in standalone PDPs only. We analyze data for individuals enrolled in their Part
D plan for the full year in each year pair of analysis and who had at least one claim in
each year. There are 451, 632 sample enrollees in 2006-7; 1, 126, 682 sample enrollees in
2007-8; and 1, 129, 200 enrollees in 2008-9. Sample period 2006-7 included 1,372 plans,
while 2007-8 and 2008-9 each included over 1,700 plans.7 Summary statistics on sample
plans and enrollees are shown in Table 1. The majority of sample enrollees are white
and female, with a mean age of 75. Between the first and second year of each year pair,
a small proportion (9-11%) of enrollees switched plans.
The standard plan thresholds moved in each year of the program; the standard
7The sample in 2006-7 is smaller due to our focus on individuals enrolled for the full year of each
year pair. 2006, the first year of our sample and of the Part D program, had an extended enrollment
period through May. Our results are not sensitive to the inclusion of individuals enrolling later in 2006.
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Table 1: Summary Statistics
Num.%Beneficiaries
Num.%Plans
%%White
%%Black
%%Female
Age
%%Switchers
Year%1 Year%2 Year%1 Year%2 Year%1 Year%2
Deductible 250 265 265 275 275 295
Donut%Threshold 2,250 2,400 2,400 2,510 2,510 2,700
Year%1 Year%2 Year%1 Year%2 Year%1 Year%2
%%No%Deductible 73.41% 78.65% 77.60% 79.51% 79.43% 79.06%
%%Standard%Deductible 24.04% 19.30% 20.48% 19.65% 19.58% 17.66%
%%Full%Donut%Coverage 6.09% 2.18% 1.43% 0.00% 0.00% 0.00%
%%Any%Donut%Coverage 13.74% 19.82% 16.35% 14.18% 13.83% 13.05%
Year%1 Year%2 Year%1 Year%2 Year%1 Year%2
Mean%Q 1,233 1,409 1,220 1,327 1,274 1,344
(Std.%Dev.) 827 867 836 863 858 865
Mean%Exp. $2,108 $2,355 $1,981 $2,078 $1,997 $2,121
(Std.%Dev.) $2,187 $2,688 $2,380 $2,729 $2,626 $3,108
Notes:%Table%displays%enrollee%and%plan%summary%statistics%for%full%20%%random%sample%of%unsubsidized,%
elderly%Part%D%enrollees%enrolled%continuously%in%standalone%PDPs%throughout%both%years%of%each%year%pair%
(Medicare%Advantage%and%employerYsponsored%enrollees%excluded).%In%addition,%we%exclude%from%our%
sample%enrollees%with%zero%claims%in%either%year%of%the%year%pair.
Standard'Plan'Features
Sample'Plan'Characteristics
Sample'Consumption
74.52 75.30 75.29
11.06% 9.65% 9.98%
2.35% 3.05% 3.05%
62.28% 62.94% 62.53%
1,372 1,720 1,722
95.93% 94.94% 94.92%
2006Y7%Sample 2007Y8%Sample 2008Y9%Sample
Mean'Sample'Characteristics
451,632 1,126,682 1,129,200
deductible increased from $250 to $295 between 2006 and 2009, and the standard donut
threshold increased from $2,250 to $2,700. However, as noted above, the majority of
enrollees were not enrolled in standard Part D plans. Between 18 and 24% of enrollees
were in plans with the standard deductible, but 70-80% of enrollees were in plans with no
deductible, and a small fringe of enrollees were in plans with positive, but nonstandard,
deductibles. Furthermore, some enrollees had coverage in the donut hole; between 2006
and 2009, the proportion of sample enrollees with any donut hole coverage ranged from
13 to 20%.
Sample enrollees purchased 1,200 to 1,400 days’ supply of prescription drugs per
year on average, for a total expenditure (out-of-pocket plus plan expenditure) of about
$2,000 to $2,400 per year. Note that, due to the extended enrollment period in the first
year of the program, individuals enrolled throughout the entirety of 2006 had higher
consumption than the average sample enrollee in later year pairs, as would be expected
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if sicker enrollees signed up earlier in 2006.
Our analyses require a single actual price and price instrument for each enrollee,
for each coverage phase, for each year of each sample year pair. We construct actual
prices and price instruments in each coverage phase using plan coverage information at
the coverage phase-drug (NDC) level, and aggregate those phases using enrollee-specific
quantity weights based on days supply of drugs consumed.8 For year pair (year 1,year
2), the actual price in phase c of year y is the weighted average price the individual
would face in phase c given the year y plan’s year y cost-sharing rules; weights use the
individual’s year y consumption (days supply) across all sample drugs observed. That
is, the price Picy for individual i enrolled in plan p in coverage phase c, for year y of year
pair year 1-year 2, is defined as
Picy =
∑
d∈Di,cs
CSdcy,p ∗RPdy,p ∗ widy +
∑
d∈Di,cp
CPdcy,p ∗ widy
where CSdcy,p and CPdcy,p are coverage phase-specific coinsurance rates and copays,
respectively, for drug d in plan p, RPdy,p is retail price for drug d in plan p, and the
consumption weight for drug d is calculated as
widy = qid,y/
∑
d∈Di,y
qid,y
using observed quantity consumed qid,y for each individual-drug-year combination. Di,y
is the set of all drugs consumed by individual i in year y. Prices are for 30-day supplies
of drugs. The retail price for a given plan-drug-year combination is calculated as the
average retail price (total expenditure per 30-day supply) across all observations of that
plan-drug combination in the claims data for that year.9
The price instrument in phase c of year y is the weighted average price the individual
would face in phase c given the year 1 plan’s year y cost-sharing rules; weights use the
individual’s year 1 consumption. For coinsurances, we apply the coinsurance rate to the
retail price appropriate for the given plan-drug combination in year 1. That is, the IV
8See Appendix A for a detailed example.
9When possible, claims for 30-day supplies only are used to calculate average retail prices. When 30-
day supply claims are not observed for particular plan-drug combinations, retail price per 30-day supply
is imputed by scaling average prices per one-day supplies observed in claims for all other quantities.
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price P IVicy is defined as
P IVicy =
∑
d∈Di,cs
CSdcy,p(year1) ∗RPd,year1,pooled ∗ wid,year1 +
∑
d∈Di,cp
CPdcy,p(year1) ∗ wid,year1.
Variation in the instrumental variable prices in the first year of each year pair are
shown in the left panel of Table 2. As in the standard plan, the average price decreases,
then increases, then decreases again as one moves from the deductible to the initial
coverage range (ICR), from the ICR to the donut hole, and from the donut hole to the
catastrophic phase. Average differences between phases are not as large as they would
be in the standard plan (which has 100% coinsurance in the deductible and donut, 25%
coinsurance in the ICR), because many enrollees have no deductible (in which case the
“deductible” price in the Table is effectively the ICR price), and some enrollees have
coverage in the donut hole.
IV price differences by coverage phase and year pair are shown in the right panel
of Table 2. Note that, because plan choice, consumption weights, and retail prices are
held fixed at year 1 values, conditional on those year 1 variables, price differences are a
function only of year 1 plan cost-sharing changes between year 1 and year 2. For the
sake of brevity, price differences are shown only for the ICR and donut hole.10
In looking across the three year pairs of our analysis sample, we note several patterns
of interest. First, the ICR and donut price differences have both negative and positive
values, but are skewed positive, so that, within a given contract, the average enrollee
experiences diminishing plan generosity for their fixed bundle of drugs between years
1 and 2. This is particularly striking when we consider the second and third columns
of the left panel of Table 2. These columns show that both median and average prices
across existing and new plans actually decrease between 2006 and 2008, indicating that
changes in generosity over time impact existing enrollees less favorably than new enrollees
(a similar pattern applies to premiums for new vs. existing enrollees, as documented in
Ericson (2012) – this phenomenon is termed invest-then-harvest behavior in the context
of premium-setting). Second, our variation based on cost-sharing only, and not using
10Individuals with deductibles in both years of the year pair have no effective IV variation in the
deductible because retail prices are held fixed across years. Similarly, catastrophic price variation is
based only on retail prices and cost-sharing minimums, the former of which are held fixed between
years in the IV and the latter of which vary across years, but not across plans. Thus, the majority
of our variation within coverage phase comes from the ICR and donut hole cost-sharing changes. In
some analyses below, we also analyze responses to variation coming from changes in the location of
deductible thresholds between years.
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Table 2: Sample Price Instrument Variation
Ded ICR Donut Catas ICR Donut
N 451,632 451,632 451,632 451,632 451,632 95,537
5th8Prctile 5.55 4.83 12.65 2.07 A4.12 A15.84
Median 20.16 15.23 45.46 3.80 0.00 0.00
95th8Prctile 69.82 31.56 98.46 5.73 8.51 46.71
Mean 26.81 16.58 50.80 3.99 1.01 5.64
Std.8Dev. 31.43 14.73 60.12 2.98 7.93 36.77
N 1,126,682 1,126,682 1,126,682 1,126,682 1,126,682 187,139
5th8Prctile 5.00 3.68 10.00 2.15 A3.86 A5.00
Median 16.83 13.62 42.60 3.69 0.58 0.00
95th8Prctile 63.29 30.80 101.99 5.93 9.00 32.37
Mean 23.04 15.41 49.62 3.95 1.32 3.49
Std.8Dev. 34.65 15.76 60.02 2.89 7.10 20.04
N 1,129,200 1,129,200 1,129,200 1,129,200 1,129,200 159,486
5th8Prctile 4.00 2.79 9.23 2.25 A1.98 A1.04
Median 14.79 12.02 40.38 3.52 1.89 0.00
95th8Prctile 62.95 31.52 106.84 6.14 12.75 6.07
Mean 21.88 14.50 49.19 3.90 3.19 1.28
Std.8Dev. 44.22 28.47 98.43 4.83 7.33 16.54
Price8Year81 Price8Year828A8Price8Year81
Year8Pair:82006A2007
Year8Pair:82007A2008
Year8Pair:82008A2009
Notes:8Price8instruments8generated8using8planAdrugAcoverage8phaseAspecific8costAsharing8parameters8(copays8and8coinsurances)8and8
individual8enrolleeAspecific8consumption8weights8on8drugs.8For8prices8specified8as8coinsurances,8average8retail8price8for8each8planAdrug8
combination8used8as8the8basis8to8which8planAdrugAphase8coinsurances8are8applied.8EnrolleeAspecific8consumption8weights8based8on8
days8supply8used8to8generate8a8weighted8average8price8for8each8individual8in8each8coverage8phase.8For8second8year8of8each8year8pair,8
consumption8weights,8retail8prices,8and8copays/coinsurances8from8first8year8consumption8and8plan8enrollment8imposed8to8isolate8price8
effect8of8changes8in8costAsharing8characteristics8holding8consumption8and8enrollment8behavior8fixed.8Donut8price8change8shown8only8
for8plans8with8any8gap8coverage8in8either8year8(price8instrument8difference8is8mechanically8zero8for8other8plans).8888888
8888888
8888888
variation in market prices, reduces the IV donut price variation substantially. The Table
shows data only for plans with at least some donut hole coverage in one or more years,
as the IV donut price difference is zero elsewhere by construction. The variation in the
IV donut price difference is falling over time, which is consistent with the donut hole
data in Table 1 – fewer enrollees have donut hole coverage in 2009 than in 2006, and no
sample enrollees have full donut coverage in 2009, as opposed to 6% in 2006. Finally,
we note that the magnitude of the price variation generated by our instrument is still
substantial. Comparing, e.g., the 5th and 95th percentile ICR price change in 2006, a
difference of $12.63 per 30 days supply would translate to more than a $500 difference
in OOP costs given mean year 1 consumption.
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5 Illustrative Example – Donut Hole Coverage
As an illustrative example of our identification strategy, we start by considering how
individuals respond to changes in donut hole coverage, all else equal. To isolate the
consumption response to the donut hole coverage change only, we take all the plans in
2006-7 and match based on having the exact same coverage thresholds in both 2006
and 2007 and the same donut hole coverage in 2006, and we impose that matches have
similar prices in year 1 and prior to the donut hole in year 2. Within those matched
plans, we select matched pairs that have different prices in the donut hole in year 2.11
Taking unique plan matches only, we obtain a large sample of 97,330 individuals in
matched plans, where plans that either dropped generic coverage between 2006 and
2007 or added it were matched to plans which did not change their donut hole coverage
between years.12
Figure 1 shows a comparison of cumulative out-of-pocket cost as a function of total
days supply purchased for “high donut” vs. “low donut” matched plans. The plans
within each pair have similar ICR cost-sharing ($19 per 30-day supply on average);
however, across all plan pairs, the average out-of-pocket cost in the donut hole for a
30-day supply of drugs is $53 in the “high donut” plan vs. $46 in the “low donut”
plan. Accordingly, we see that cumulative out-of-pocket cost is equivalent in the high-
and low-donut plans until the donut threshold is reached, at which point the high-donut
plan’s out-of-pocket cost increases more steeply.13 Note that the “low donut” plans are
still less generous in the donut hole than in the ICR (there is still a “kink” at the donut
threshold) because they at most only cover generic drugs in the donut hole.
Using this sample, we ran a differences-in-differences regression of the year-to-year
11In the results shown, we have imposed that: the difference between plans’ donut prices in 2007
exceeds $3; that the difference between plans’ deductible prices in 2007 is less than $1; and that the
difference between plans’ 2006 weighted average prices (using pooled sample consumption weights based
on days supply) and the difference between plans’ 2007 ICR prices are each less than one-third the 2007
donut price difference between plans. Results are not sensitive to changes in these matching parameters,
though more restrictive matches have larger standard errors.
12Many plans have multiple matches based on the criteria above. To obtain unique matches, we
iterate over matches based on size – we find the best match (the match with the most similar 2006 and
pre-donut 2007 prices and least similar 2007 donut prices) for the largest matched plan (by enrollment),
remove both plans from the sample, and iterate on this procedure until each match is unique. In the
final sample, we have 94 matched pairs with 188 plans total.
13The plans have the same catastrophic threshold, but the catastrophic threshold is reached more
quickly in high-donut price plans, because crossing the catastrophic threshold is defined based on cumu-
lative out-of-pocket costs rather than on total expenditure. Both the deductible and donut thresholds
in Part D plans are reached based on expenditure. None of the matched plans have deductibles.
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Figure 1: Matched Plans – OOP Cost Comparison (2007)
Notes:'Average'cumulative'out2of2pocket'(OOP)'spending'as'a'function'of'cumulative'months2supply'purchased'based'on'prices'
in'188'matched'plans.'Plans'are'matched'based'on'similarity'in'both'2006'coverage'characteristics'and'2007'pre2donut'coverage'
characteristics'and'dissimilarity'in'2007'donut'coverage.'Details'in'text.'"Low'Donut"'plans'are'those'with'lower'prices'(generic'
coverage)'in'the'donut'hole'in'2007'(average'OOP'price'$46);'"High'Donut"'plans'are'those'with'higher'prices'(no'coverage)'in'
the'donut'hole'in'2007'(average'OOP'price'$53).
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annual or quarterly change in quantity purchased on plan pair fixed effects and a dummy
for being in the “high donut hole price” plan in the second year (2007). These regressions
include controls for individual demographics and individual health care consumption
patterns. The former include dummies for age, sex, race, and state. The latter include
rich controls for total base year (2006) individual drug consumption and prices (polyno-
mial controls for coverage phase-specific prices, and 100 quantiles each of days supply
purchased, total drug expenditure, out-of-pocket (OOP) drug expenditure, and retail
price per prescription) and total base year (2006) individual medical spending (dum-
mies for nonzero spending overall and in several subcategories – office visits, inpatient
emergency, inpatient non-emergency, outpatient, and other – as well as polynomial con-
trols for medical spending overall and level controls for spending in each subcategory).
We also include dummies for having any drug spending in each generic therapeutic class
(GTC), which is a summary measure of target medical condition.14 We interact the
14Each unique drug (NDC) is classified by the company First Data Bank as falling under a particular
generic therapeutic class based on the medical condition it treats. There are forty such classes, the
most popular of which are “Cardiovascular,” “Autonomic Drugs,” “Cardiac Drugs,” and “Diuretics”
among our sample enrollees. The GTC by generic dummies account for the potential that, for example,
individuals who tend to take cardiac drugs may exhibit different utilization trends than those who take
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GTC dummies with separate indicators for generic and branded drugs. These controls
incorporate the possibility that underlying utilization trends may differ by type of illness
and preferences over branded vs. generic drugs. Finally, we include dummies for each
plan pair (noting that each plan in a plan pair has the same year 1 budget set and
pre-donut year 2 budget set).
Q2it −Q1it = α + β ∗ dHighDonutChg + δ ∗Xij
The results in Table 3 show several striking facts. First, enrollees’ consumption
responds negatively to lower donut hole coverage. Second, the response is large (-0.085)
and significant at the end of the year, when people are more likely to have entered the
donut hole, while it is undetectable in the first quarter of the year. Myopia is one possible
explanation for this pattern – in the next Section, we present more direct evidence that
it plays a substantial role.15
Table 3: Differences-in-Differences Results, Donut Hole Coverage Dummy, Matched Plan
Enrollees
Obs Coef
Full+Year 97,330 40.025 0.016
Q1 78,867 0.002 0.018
Q2 78,867 40.031 0.015 *
Q3 78,867 40.048 0.015 **
Q4 78,867 40.085 0.016 **
SE
Notes+and+Sources:+Results+of+full+year+and+quarterly+regressions+of+200647+
consumption+change+on+a+dummy+for+being+in+a+"high+year+2+donut"+plan.+
January+enrollees+only.+In+full+year+runs,+individuals+with+zero+quantity+in+either+
year+dropped.+In+quarterly+runs,+individuals+with+zero+consumption+in+any+
quarter+of+either+year+dropped.+Regression+controls+in+text.+Superscript+"**"+
indicates+significance+at+the+1%+level;+superscript+"*"+indicates+significance+at+the+
5%+level.++++++++++++++
++++++++++++++
++++++++++++++
++++++++++++++
++++++++++++++
++++++++++++++
anti arthritics, even absent differential price changes between sample years.
15Note that we do not necessarily expect the full year coefficients to be a mechanical average of the
quarterly coefficients, because the specification is run in logs and because the quarterly analyses are
restricted to individuals with positive claims in each quarter and thus to a higher-utilization baseline
enrollee. Qualitative patterns are insensitive to this restriction.
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6 Model and Results
In this Section, we outline the baseline model of optimal consumption with nonlinear
budget sets and describe several ways in which consumption may deviate from this
model in practice. We then present and estimate a flexible empirical model that can
accommodate these deviations.
We begin with a simple model, in which forward-looking, rational individuals opti-
mize their consumption of a single prescription drug over the course of the year with no
uncertainty. Suppose individuals maximize their utility u(.) by choosing consumption
qt for each t = 1, ..., T . Suppose also that they face a nonlinear budget set with the
following out-of-pocket expenditure function over total quantity Q =
∑T
t=1 qt purchased
in the year:
EOOP (Q) =
{
p1 ∗Q if Q ≤ X¯R
p1 ∗ X¯R + p2 ∗
(
Q− X¯
R
)
if Q > X¯
R
where out-of-pocket prices p1 and p2 are indexed by coverage phase (p1 being the first
coverage phase encountered, p2 being the second), there is a single coverage threshold
at X¯, and the drug’s retail price (total price paid by the plan plus enrollee) is R. As in
many nonlinear budget sets, the effective price paid by consumers changes as a function
of total spending: for the first X¯
R
units, the unit price is p1; for the remaining
(
Q− X¯
R
)
units, the unit price is p2. For example, X¯ could represent a convex budget set kink with
out-of-pocket prices p1 < p2 as would occur at the Medicare Part D donut threshold.
In a 2006 Part D plan with standard cost-sharing and no deductible, for a single $100
drug, we would have p1 = $25, p2 = R = $100, and X¯ = $2, 250.
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Given perfectly forward-looking behavior, no uncertainty or discounting, and u(.)
constant across t, the dynamic problem collapses to the static choice of prescription
drug quantity Q for the full year. The solution for a general quasiconcave, continuously
differentiable utility function over prescription drugs (assuming linear utility for the
16We focus on response to ICR and donut hole prices in this project, as very few individuals end the
year in the deductible or catastrophic phase in Medicare Part D. However, the model easily generalizes
to accommodate more coverage phases.
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numeraire) will be:
Q∗ =

u˜
′−1(p1) if u˜′
(
X¯
R
)
≤ p1
X¯
R
if p1 < u˜
′
(
X¯
R
)
≤ p2
u˜
′−1(p2) if u˜′
(
X¯
R
)
> p2
(1)
where u˜(Q) =
∑T
t=1 u(
Q
T
). In the optimum, individuals consume either as they would
under a linear price schedule with p1 or p2 or they “bunch” at the coverage threshold
X¯.17 This makes intuitive sense: those consumers whose marginal utility of consumption
at X¯/R is less than p1 prefer to consume below the threshold X¯/R at linear price p1,
and would reduce their consumption even more under the higher linear price p2; their
consumption is thus unaffected by the nonlinearity of the budget set. Similarly, those
consumers whose marginal utility of consumption at X¯/R exceeds p2 prefer to consume
past the threshold under linear price p2, and would continue to consume beyond the
threshold if prices for marginal or inframarginal units drop (the additional savings on
inframarginal units are akin to a transfer given the assumed quasilinear utility function).
Those consumers who would be willing to pay p1 for an additional unit of consumption
at the kink but who are not willing to pay the post-kink price p2 for that unit will bunch
at the donut hole by consuming exactly X¯/R for the year.
In sum, in the somewhat restrictive model described above where consumers have
perfect knowledge regarding (and are perfectly attentive to) their price schedule and
prescription drug needs throughout the year, we predict that total consumption for
many price-parameter combinations will be a function of marginal (end of year) price
as in a linear budget set model. In the next Section, we relax the above model to allow
for dynamic decision-making due to myopia and account for the role of uncertainty.
17If we expand the model to allow for kinks at the deductible and catastrophic thresholds, the model
optimum is similar, but there is no “bunching” at deductible or catastrophic thresholds. At thresholds
where the out-of-pocket price decreases, the individual would prefer to “jump” past the threshold – if
an individual’s marginal utility for an additional unit of consumption exceeds the pre-threshold price
p1, then it also exceeds p2 < p1.
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6.1 Dynamic Consumption Responses
Now, we modify the model slightly and assume that individuals make their prescription
drug utilization choices in each of T periods according to the following value functions:
VT (XT ) = WT (XT ) = maxqu(q)− EOOP (XT , q)
Vt(Xt) = maxqu(q)− EOOP (Xt, q) + βWt+1(Xt + q ∗R) ∀t < T
Wt(Xt) = maxqu(q)− EOOP (Xt, q) +Wt+1(Xt + q ∗R).
Here, VT represents the optimal value the individual can achieve in the final period T
given total cumulative expenditure XT in all previous periods 1, 2, ...T − 1. Similarly, Vt
is the value function from period t forward given previous expenditure Xt, where total
utility in all future periods Wt is discounted by β. That is, we allow for hyperbolic
discounting as in a β − δ discounting model, but impose that δ = 1.18 Consumption in
the final period T will be the solution to the static optimization problem as in equation
(1) for a nonlinear budget set with a kink at X˜ = max{X¯−XT , 0}. Consumption in t =
1, ..., T−1 will maximize current-period utility u(q) less out-of-pocket expenditure EOOP
plus (discounted) future utility; current consumption impacts future value Wt+1(Xt +
q ∗R) through the nonlinearities in the budget set.
If we further assume that u(.) is quadratic:
u(q) = α˜0 + α˜1 ∗ q + α˜2 ∗ q2
then the solution will be such that, for all individuals ending both the current period
and the year in the interior of a coverage phase, consumption in each period is given by:
qit = α1t + α2t(βMPi,y + (1− β)CPit,y) (2)
with α1t = − α˜1t2α˜2t and α2t = 12α˜2t . The terms MPi,y and CPit,y denote the marginal end
of year price and the current price in period t, respectively. Consumption in each such
18Given that all dynamic decisions are made within the relatively short time horizon of a single year
(Part D contracts exist for a maximum of one year, and the only dynamic consideration in this simple
model is the effect of current consumption on future price within the current year’s contract), it seems
reasonable to assume an exponential discount factor of 1. We use hyperbolic discounting to capture
“myopia” in the form of present-biased price responses, but we note that such responses could be the
result of multiple models of decision-making, including one in which consumers are not attentive to the
full schedule of prices that they face (as opposed to being perfectly attentive, but valuing future returns
lower than current returns).
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period will be a function of a weighted average of current price and future price, where
the weight on future price equals the discount factor β. Hence, the coefficients on current
price and marginal price will equal the overall price sensitivity term α2t multiplied by
the weights 1 − β and β, respectively, due to dynamic preferences. This parallels the
current-future price specification in Aron-Dine, et al. (2014).
In practice, current and future prices may be complicated objects for individuals
to calculate, and consumers may further be confused about the role of future prices
in their optimal consumption path. As noted above, research has found that in other
settings with nonlinear pricing (such as electricity markets), consumers may respond to
average prices rather than to expected marginal prices. In order to account for the fact
that the current-future model derived above may impose the wrong model of consumer
behavior, we consider a more flexible specification of the dynamic utilization model
which subsumes the current/future model without imposing a specific functional form
on how individuals respond to different segments of the budget set. Specifically, we
regress quarterly quantity consumed on the initial coverage range (ICR) price and the
donut hole price.19
In the rational model in which consumers respond only to marginal end of year prices
(β = 1) and know exactly what these prices will be (no uncertainty), the extent to which
consumers respond to prices in each coverage range of their budget set will depend on
the probability that each coverage range is marginal. By breaking the marginal price
MP down into its component parts, we can write:
qit = α1 + α2MPi,y
= α1 + α21(mi = ICR) ∗ PICR + α21(mi = Donut) ∗ PDonut
where 1(mi = C) is an indicator for the event that coverage phase C is the marginal
coverage phase for individual i. Rewriting this as
qit = α1 + αICR ∗ PICR + αDonut ∗ PDonut,
the coverage phase-specific coefficients will be such that E(αICR) = E(α2 ∗ 1(mi =
ICR)) = α2 ∗ Pr(mi = ICR) and similarly for the donut hole price coefficient.20 In
19The price variation analyzed in this study is primarily in the initial coverage phase and donut hole,
but some plans also have nonzero deductible thresholds in one year or both; in subsequent Sections, we
address this variation as well.
20We are implicitly assuming here that the LATE estimated given our instrument will equal the
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the linear demand specification (quadratic utility), the same result holds even if there
is uncertainty about which coverage range is current/marginal as long as price changes
do not alter the probabilities of coverage phase transitions and as long as there is no
bunching. For example, our estimates will be the same in the linear model whether
beneficiaries A and B both believe they have a 50% chance of hitting the donut hole
and respond half as much as they otherwise would or whether A believes he has a 100%
chance of hitting the donut hole and B a 0% chance.21 In our baseline analyses, we
attempt to minimize uncertainty regarding coverage phase transitions (as well as the
potential for endogenous coverage phase transitions in response to prices) by focusing
our analyses on individuals well away from kink points. In Appendix D, we examine
the robustness of this approach using more conservative sample restrictions and a richer
consumption model that includes nonlinear responses and uncertainty; the results with
these modifications are unchanged.
In the more general current/future model considered above, the specification as a
function of coverage phase prices becomes:
qit = α1 + α2 ∗ (β ∗MPit,y + (1− β) ∗ CPi,y)
= α1 + α2 ∗ β ∗ (1(mi = ICR) ∗ PICR + 1(mi = Donut) ∗ PDonut)
+ α2 ∗ (1− β) ∗ (1(ci = ICR) ∗ PICR + 1(ci = Donut) ∗ PDonut)
= α1 + αICR ∗ PICR + αDonut ∗ PDonut,
where 1(ci = C) is an indicator for the event that C is the current coverage range
for individual i. This implies that the coefficients on the ICR and donut respec-
tively will be E(αICR) = α2 ∗ (β ∗ Pr(mi = ICR) + (1 − β) ∗ Pr(ci = ICR)) and
E(αdonut) = α2 ∗ (β ∗ P (mi = Donut) + (1− β) ∗ P (ci = Donut)). In other words, this
reduced form model of consumption responding to ICR and donut prices subsumes a
model of consumption responding to current and future price; however, we do not require
that the consumption response to coverage phase prices be scaled by current and future
probability weights under a specific model of expectations, and can accommodate behav-
ior such as “schmeduling.” In the following Section, we estimate this flexible model; we
ATE. This assumption is equivalent to asking whether compliers – consumers for whom the price
change of their year t-1 plan impacts prices today – have systematically different marginal prices than
non-compliers. If they do, the above probabilities will be the probabilities among compliers rather than
among the whole sample.
21In the log model, this result no longer holds exactly. Instead, log(Ci) = α1 + α2log(Ei(Pi)) where
Ei(Pi) =
∑
c P (coverage rangei = c)Pic where Pic is the price in each coverage range.
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then use the reduced form results to examine performance of the current-future model
(vs. alternative models of expectations and weighting) in this setting.
6.2 Dynamic Results – Individuals in Interior of Coverage Phases
The dynamic specification outlined above only holds for individuals ending both the
current and marginal periods in the interior of a coverage phase. In this Section, we
describe our first empirical specification, which models dynamic (quarterly) consumption
as a function of ICR and donut prices for just such individuals – individuals for whom the
donut is marginal and individuals for whom the ICR is marginal (excluding individuals
likely to be near the threshold between the two groups). Specifically, we look only at
individuals consuming less than or equal to $1,500 in 2006 and, separately, at individuals
consuming between $3,000 and $5,000 in 2006; we restrict the samples similarly for 2007
and 2008, adjusting the cutoffs in each year pair to account for secular trends in standard
plan thresholds. The first group is a set of individuals who are almost certainly going
to have the ICR price as their marginal price; the second group is a set of individuals
who are almost certainly going to have the donut price as their marginal price.
Of course, to the extent that prescription drug needs evolve over time and in the
presence of substantial uncertainty about prescription drug needs, this approach would
be imperfect. In practice, 3.7% of individuals in the low-spending group cross the donut
hole threshold in year 2 and 14.2% of individuals in the high-spending group do not.
Thus, our sample restrictions do not completely eliminate switching behavior and may
be impacted by uncertainty. Further, the extent to which coverage phase switching re-
sponds endogenously to prices may bring an additional source of bias. However, we can
use these samples to examine behavior in the presence of far more limited marginal price
uncertainty and scope for switching than we would expect in the full sample. In Ap-
pendix D, we limit the sample further to eliminate bias due to switching uncertainty and
estimate a more general model with endogenous switching. Our results are nearly iden-
tical to the baseline results, implying that the linearized model with sample restrictions
relative to budget set kinks performs quite well.
We empirically estimate the model above, with consumption as a function of the ICR
and donut price, assuming power utility (motivating a log functional form). The log
functional form is employed because the distribution of consumption is skewed positive
and there is a heavy upper tail even within the restricted regression sample. This yields
an equation of the form: log(qit) = α1 + αt,ICRlog(Pi,y,ICR) + αt,Donutlog(Pi,y,Donut) for
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individual i in period t of year y. For each quarter and each pair of years, we take
differences across years, yielding the equation:
log(qi,t,y)− log(qi,t,y−1) = α1t + αt,ICR(log(Pi,y,ICR)− log(Pi,y−1,ICR))
+ αt,Donut(log(Pi,y,Donut)− log(Pi,y−1,Donut)) + uit
As described in Section 4, in this and each of the following regressions, we use an
instrumental variables strategy based on plan choice inertia. For a given pair of years,
cost-sharing characteristics used to generate the year 2 price instrument are the year
2 cost-sharing parameters (copays/coinsurances, coverage thresholds, etc.) of the year
1 chosen plan. In all regressions, we include all the controls from the paired analysis
as well as rich controls for plan characteristics in order to generate the apples-to-apples
comparison described in Section 3 – two individuals with identical plans and observables
in 2006, one of whom experiences a change in cost-sharing in 2007. As this exercise does
not explicitly pair plans based on year 1 plan characteristics, we also control for dummies
for year 1 deductible and donut hole coverage and thresholds, polynomials of year 1
prices in each budget segment, and 50 quantiles each of year 1 quantity (days supply),
expenditure, out-of-pocket spending, and average retail price of drugs consumed for the
average person in the year 1 plan.22
Consider first the low-spending group. Results are in Table 4. The proportion of
individuals in their marginal coverage phase is slightly increasing over the course of the
year (beginning at 83% in Q1, ending at 97% in Q4) as the small proportion of individuals
with deductibles enter the ICR.23 Considering each year pair individually, the ICR price
response is either flat (2006-7) or slightly increasing in magnitude over the course of
the year (2007-8 and 2008-9). On balance, the results for all years pooled show that
the ICR response is fairly flat across quarters even though the proportion of individuals
in the marginal coverage phase increases slightly – given that most individuals (83%)
either do not have a deductible or exit the deductible in Q1, these results are limited in
their usefulness for detecting myopic behavior. We do not observe a substantial response
of low-spending individuals with respect to the donut hole price, as would be expected
given even imperfectly forward-looking behavior – in some samples, we observe a small
positive sign on the donut hole price. The magnitude of the static price elasticities
22In the paired analysis in the previous section, these plan characteristics would be collinear with the
plan pair fixed effects and “high donut” dummy.
23The remaining 3% do not exit the deductible in year 1.
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suggested by these estimates is on the lower end of the elasticities found in the literature
(-0.04 to -0.05).
Table 4: Results of Quarterly ICR and Donut Price Regressions – Low-Spending Group
Period Price Coef Coef Coef Coef
Q1 ICR .0.051 0.006 ** .0.047 0.014 ** .0.022 0.010 * .0.061 0.009 **
Q1 Donut 0.023 0.008 ** .0.008 0.023 0.022 0.011 * 0.018 0.010
Q2 ICR .0.041 0.007 ** .0.046 0.018 * .0.023 0.010 * .0.056 0.009 **
Q2 Donut 0.026 0.008 ** 0.041 0.026 0.017 0.011 0.029 0.011 *
Q3 ICR .0.043 0.007 ** .0.057 0.017 ** .0.032 0.011 ** .0.044 0.008 **
Q3 Donut 0.008 0.009 0.026 0.027 0.000 0.013 0.003 0.012
Q4 ICR .0.051 0.009 ** .0.039 0.016 * .0.045 0.015 ** .0.067 0.011 **
Q4 Donut .0.011 0.011 .0.051 0.027 .0.008 0.016 .0.005 0.017
%?in?
ICR
Notes:?Results?of?quarterly?regressions?of?log?consumption?change?on?log?change?in?ICR?and?donut?prices,?low.
spending?individuals?only.?Individuals?with?positive?consumption?in?each?quarter?only.?N=919,650?across?all?years;?
N=128,412,?388,454,?and?402,784?in?year?pairs?2006.7,?2007.8,?and?2008.9,?respectively.?Proportion?of?(pooled?
years)?sample?for?whom?initial?coverage?range?(ICR)?is?marginal?in?each?quarter?of?first?year?noted?next?to?
estimated?coefficients.?Superscript?(**)?indicates?significance?at?the?1%?level;?superscript?(*)?indicates?significance?
at?the?5%?level.
83.0%
92.1%
95.4%
97.0%
All?Years?Pooled 2006.7 2007.8 2008.9
SE SESE SE
Consider next the high-spending group. Results are in Table 5. Among high-spending
individuals, there is a steep increase in the proportion of individuals in the marginal
coverage phase (the donut hole) between quarters 1 and 4 (rising from 0.5% to 95% based
on year 1 consumption, the latter number reflecting that some high-spending individuals
are in plans with no donut hole). Concurrent with this increase, we observe also that
the donut hole price response is quite steep over the course of the year in each year pair
individually and in the regression that pools all year pairs. High-spending individuals
have a large and significant donut price response in quarter 4 (ranging from -0.14 to
-0.24 in the individual year pair samples, equalling -0.164 in the pooled analysis) which
is significantly larger than the donut response at the beginning of the year (ranging from
-0.05 to -0.09 in the individual year pair samples, equalling -0.053 in the pooled analysis).
This fact provides striking evidence of myopia, given the low degree of uncertainty that
high-spending individuals will be in the donut hole at the end of the year – individuals
are on average more than three times as responsive to donut price changes when they are
actually in the donut hole than they are prior to crossing the donut threshold. Regarding
the “spot” price enrollees face prior to the donut hole (the ICR price): in 2006-7 and
2007-8, individuals never significantly respond to the ICR price change, while in 2008-9,
the ICR price coefficient is -0.05 to -0.06 at the beginning of the year. The pooled ICR
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response is significant but small in Q1 and Q2 (-0.023 to -0.034) but shrinks toward zero
in Q3 and Q4. This pattern is also consistent with myopia.
Table 5: Results of Quarterly ICR and Donut Price Regressions – High-Spending Group
Period Price Coef Coef Coef Coef
Q1 ICR .0.034 0.010 ** .0.018 0.018 .0.012 0.015 .0.057 0.017 **
Q1 Donut .0.053 0.014 ** .0.054 0.021 ** .0.050 0.024 * .0.088 0.030 **
Q2 ICR .0.023 0.011 * .0.003 0.021 .0.013 0.015 .0.053 0.017 **
Q2 Donut .0.073 0.015 ** .0.077 0.025 ** .0.069 0.022 ** .0.085 0.030 **
Q3 ICR .0.023 0.012 .0.005 0.022 .0.020 0.017 .0.029 0.018
Q3 Donut .0.086 0.018 ** .0.111 0.029 ** .0.116 0.031 ** .0.069 0.028 *
Q4 ICR .0.008 0.014 .0.021 0.025 .0.017 0.021 0.017 0.022
Q4 Donut .0.164 0.025 ** .0.167 0.027 ** .0.243 0.047 ** .0.138 0.034 **
%?in?
Donut
0.5%
22.2%
88.0%
94.9%
Notes:?Results?of?quarterly?regressions?of?log?consumption?change?on?log?change?in?ICR?and?donut?prices,?high.
spending?individuals?only.?Individuals?with?positive?consumption?in?each?quarter?only.?N=294,898?across?all?years;?
N=61,198,?127,052,?and?106,648?in?year?pairs?2006.7,?2007.8,?and?2008.9,?respectively.?Proportion?of?(pooled?
years)?sample?for?whom?donut?hole?is?marginal?in?each?quarter?of?first?year?noted?next?to?estimated?coefficients.?
Superscript?(**)?indicates?significance?at?the?1%?level;?superscript?(*)?indicates?significance?at?the?5%?level.
All?Years?Pooled 2006.7 2007.8 2008.9
SE SE SE SE
The above results provide estimates of a small, significant price elasticity of demand
for prescription drugs throughout the spending distribution. We also observe strong
evidence of myopic utilization behavior, in that enrollees’ marginal price response is
much more evident at the end of the year, once they have entered their marginal coverage
phase. In the next Section, we examine whether individuals respond to “prices” other
than the out-of-pocket costs that should be most relevant for them given their observed
drug consumption patterns.
6.3 Salience Results
As discussed in Section 1, choosing optimal consumption in a Part D plan requires not
only dynamic optimization with a nonlinear budget set, but also a calculation of within-
phase prices given the particular prescription drugs each enrollee takes (or may take).
In the case of cost-sharing specified as copays, the enrollee must consult the formulary
and plan benefit description for each drug and aggregate; in the case of coinsurances (as
are generally used to determine cost-sharing at least in the deductible and donut hole),
the enrollee must also know each drug’s retail price to determine his or her cost-sharing.
Notably, although consumers may learn about retail prices and/or cost-sharing for the
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current coverage phase when they purchase a drug at the pharmacy, they may yet have
residual uncertainty about prices in coverage phases they could encounter in the future.
As noted by a number of researchers, including Abaluck and Gruber (2011), Chetty,
Looney, and Kroft (2009), and Feldman, Katuscak, and Kawano (2013), consumers may
underreact to less salient indicators of price (e.g., insurance plan coverage or taxes) and
overreact to more salient indicators of price.24 To the extent that some portion of the cal-
culation exercise described above makes the phase-specific average price for an individual
enrollee’s bundle of drugs less salient than other indicators of plan coverage generosity,
the current-future price specification that results from our hyperbolic discounting model
may fail to adequately account for the full scope of individuals’ responses.
Some plan characteristics that may specifically be more salient are the presence or
absence of a deductible, and the presence or lack of donut hole coverage, each being
particularly visible in plan benefit materials and tools such as the Medicare Plan Finder
on CMS’s website. In order to account for the potential impact of more salient price
changes on consumption behavior, we next perform additional regressions of change
in quantity consumed on the initial coverage range price change, the donut hole price
change, and two variables capturing changes in deductible or donut hole coverage. That
is, we use the exact same specification as in Section 6.2, but with two additional variables.
The deductible change variable equals -1 if the deductible threshold is decreased between
years, and equals 1 if the deductible threshold is increased between years by more than
the standard deductible change (e.g., $250 to $265 between 2006 and 2007); it equals 0
otherwise.25 The second variable captures changes in categorical coverage in the donut
hole. There is ambiguity about the most appropriate variable to use in this exercise.
Some of the donut hole coverage variation encountered by our sample enrollees is of the
sort of clear variation used to estimate price sensitivity in previous work, such as the
RAND experiment or Chandra, et al. (2010); for example, whether the plan removes
coverage of branded drugs in the donut hole, or removes all donut hole coverage. Other
24Salience effects contemplated in this Section may be a function of both limited awareness of plan
characteristics and incomplete understanding of those characteristics’ implications for prices. The
latter factor was found to have an impact in the tax context in Feldman, Katuscak, and Kawano
(2013). In the health care literature specifically, survey research has found that health insurance
enrollees do not understand typical plan characteristics – in Loewenstein, et al. (2013), only 14% of
respondents were able to answer correctly four multiple choice questions about the four basic components
of traditional health insurance design: deductibles, copays, coinsurance and maximum out-of-pocket
costs; further, understanding of certain characteristics was worse than others (e.g., coinsurances were
less well understood than copays).
25For plans with any deductible in both years of the year pair, there is essentially no within-phase
price instrument variation because the deductible coinsurance equals 100%.
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donut hole coverage variation is high-dimensional and would be difficult for enrollees
to understand or translate into prices; for example, whether the plan adds coverage of
“many preferred” branded drugs. As discussed in Appendix B, we focus on nominally
large (or, as we say below, “stark”) changes in coverage, which we argue is best equipped
to capture the salience effects of interest. The variable “Stark” equals 1 if coverage for
an entire class of drugs (e.g., all generics) is dropped between year 1 and year 2, and
equals -1 if coverage for an entire class of drugs is added; it equals 0 otherwise.
The results for the full year are shown in Table 6, which shows that Part D enrollees
do respond on average to stark changes in donut hole coverage beyond such changes’
effects on expected donut hole prices. The coefficients vary across year pairs but are
negative across all years where such changes were observed for a non-negligible sample
of enrollees (i.e., other than in 2008-9 – see Appendix B for detail of “Stark” variation
by year). The pooled result indicates that a plan’s dropping generic donut hole coverage
would result in a consumption decrease of 4.3%. It is important to note here that this
result is not an artifact of the collinearity between the donut price and the “Stark”
variable – as shown in Appendix Table 6, the point estimate on the “Stark” variable is
very similar whether or not the donut price is omitted from the regression.
Table 6: Results of Full Year ICR and Donut Price Regressions, with Stark Donut
Coverage and Deductible Variables – All Enrollees
Price Coef Coef Coef Coef
ICR +0.078 0.006 ** +0.084 0.012 ** +0.066 0.011 ** +0.082 0.008 **
Donut 0.021 0.009 * 0.008 0.022 0.006 0.014 0.035 0.012 **
Ded.=Chg +0.039 0.006 ** +0.008 0.012 +0.039 0.009 ** +0.048 0.008 **
Stark +0.043 0.008 ** +0.038 0.011 ** +0.047 0.017 ** 0.009 0.027
Notes:=Results=of=full=year=regressions=of=log=consumption=change=on=log=change=in=ICR=and=donut=
prices,=as=well=as=changes=in=stark=gap=coverage=and=deductible=coverage.=Full=sample=of=2.7=million=
enrollees=included.=Superscript=(**)=indicates=significance=at=the=1%=level;=superscript=(*)=indicates=
significance=at=the=5%=level.
All=Years=Pooled 2006+7 2007+8 2008+9
SE SE SE SE
We also observe in 2007-8 and 2008-9 a substantial effect of deductible coverage on
consumption. The deductible is not marginal for the vast majority of enrollees, but
all enrollees with deductibles spend some portion of the year in that phase, so that
the deductible response may be due to myopia (overreacting to the individual-specific
effective price change earlier in the year) or to salience (reacting to the deductible based
on its visibility in benefit presentation rather than based on the implied out-of-pocket
price change).
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Table 7 shows the results of these same regressions separately for high- and low-
spending enrollees (for brevity, the regression for all years pooled is shown in the Table).
Interestingly, we observe that the “Stark” donut hole coverage response is negative and
significant even among low-spending individuals who have essentially zero probability of
reaching the donut hole – the point estimates indicate that low-spending enrollees, ob-
serving that their plan dropped (added) generic or branded coverage to their plan benefit,
would decrease (increase) annual consumption by 6% even though they never expect to
encounter the donut prices. The “Stark” coverage change response is smaller in magni-
tude for high-spending individuals, indicating a 2.5% decrease in spending among high-
spending enrollees losing gap coverage. We also observe in Table 7 that the deductible
change response is larger in magnitude for low-spending enrollees than for high-spending
enrollees, but not significantly so.26
Table 7: Results of Full Year ICR and Donut Price Regressions, with Stark Donut Cov-
erage and Deductible Variables – Low- and High-Spending Enrollees, All Years Pooled
Price Coef Coef
ICR +0.099 0.010 ** +0.026 0.008 **
Donut 0.043 0.014 ** +0.063 0.013 **
Ded.;Chg +0.033 0.009 ** +0.023 0.008 **
Stark +0.059 0.015 ** +0.025 0.010 *
Low+Spend;
Enrollees
SE
High+Spend;
Enrollees
SE
Notes:;Results;of;full;year;regressions;of;log;consumption;change;on;log;change;
in;ICR;and;donut;prices,;as;well;as;changes;in;stark;gap;coverage;and;deductible;
coverage.;All;year;pairs;pooled.;N=1,326,301;for;low+spending;enrollees;;
N=307,004;for;high+spending;enrollees.;Superscript;(**);indicates;significance;
at;the;1%;level;;superscript;(*);indicates;significance;at;the;5%;level.;;;;
Taken together, these results imply that high-level coverage changes (such as changes
in deductible or donut generosity) have a large impact on individuals’ behavior. The de-
ductible response may be further evidence of myopia. However, the significant response
26Note that we do not interpret these results as indicating a larger response by low-spending en-
rollees to changing deductible or gap coverage – consumption enters the regression in logs and thus
the coefficients for high and low spenders are not directly comparable. For example, if we scale the
“Stark” coefficients by year 1 spending, the implied linear response to the “Stark” variable is -44 among
low-spending enrollees vs. -51 among high-spending enrollees. In a model with hyperbolic discounting,
we would expect the deductible price response to vary inversely with the overall magnitude of spend-
ing, but given the standard errors and log specification, we cannot disentangle the effects of myopia
and salience using the deductible coefficients. We do observe in Table 8 in the following Section that
deductible responses are stronger at the beginning of the year than at the end of the year, which is
stronger evidence that the deductible response is driven in part by myopia.
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to stark changes in donut hole coverage goes beyond what we would expect given a
rational, forward-looking calculation of what those changes imply for marginal prices –
our most striking evidence of price salience is that observed for low-spending individuals,
who are very unlikely to encounter the donut hole during the year.
7 Structural Model Results
Our results thus far have provided evidence of significant price responses overall, sub-
stantial myopia, and price salience effects. In order to construct counterfactual estimates
for individuals outside our regression sample (i.e., near the donut hole kink), we require
a structural model of consumption behavior. An obvious candidate for this model is
the dynamic consumption model derived in Section 6.1. Indeed, in the next Section,
we show that this model fits the data well both inside and outside the regression sam-
ple. We also show that the model outperforms alternative models – both the rational
marginal price response model and the behavioral average price response model. The
model performs well even though it is estimated using linear consumption responses; in
Appendix D.2, we derive and estimate a structural model with bunching and coverage
phase switching and demonstrate that performance of the richer model is, if anything,
weakly worse than the simpler specification.
7.1 Parameter Estimates
Because our estimates are from a log-log regression specification (due to the presence of
a heavy upper tail in the regression sample) and our model of hyperbolic discounting
assumes a quadratic utility function (linear demand), this exercise requires that we lin-
earize our main (dynamic) empirical specification (including the deductible and “Stark”
donut hole coverage terms):
log(qity)− log(qit,y−1) = at +Xit ∗ δt + bICR,t ∗ (log(PICR,y)− log(PICR,y−1))
+ bDonut,t ∗ (log(PDonut,y)− log(PDonut,y−1))
+ θDed,t ∗ dedchgi + θstark,t ∗ starki + uity
The structural model we wish to link the empirical specification to (changing the
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notation from Section 6.1 slightly to accommodate our salience terms) is:27
q = α + η(βMP + (1− β)CP ) +Kd ∗ 1(dedchg = 1) +Ks ∗ 1(stark = 1).
In this model, the term α is predicted spending (in year 2) at zero prices and absent any
deductible or donut hole coverage change between year 1 and year 2. The static price
response is η – this is the price response we would observe under a linear price contract.
The hyperbolic discount factor is β. Kd and Ks capture consumption shifts between
years 1 and 2 in response to changes in the deductible and stark donut hole coverage,
respectively, which we model as distinct from the budget set responses captured by η
and β.
Letting zy be the vector of year y prices, we linearize the specification around z1.
Details are given in Appendix C. This gives us an expression for each of the coefficients
from our structural model (omitting subscripts for the sake of brevity):
α = q1 ∗ exp(a+X ∗ δ + u)(1− bICR − bDon) (3)
η ∗ (β ∗ Pr(MP = ICR) + (1− β) ∗ Pr(CP = ICR)) =
(
q1
PICR,1
)
∗ exp(a+X ∗ δ + u) ∗ bICR
(4)
η ∗ (β ∗ Pr(MP = Don) + (1− β) ∗ Pr(CP = Don)) =
(
q1
PDon,1
)
∗ exp(a+X ∗ δ + u) ∗ bDon
(5)
Kd = q1 ∗ exp(a+X ∗ δ + u) ∗ θDed (6)
Ks = q1 ∗ exp(a+X ∗ δ + u) ∗ θstark (7)
These relations show that the linear structural constant α varies with year 1 consump-
tion and enrollee characteristics, so that this exercise yields a local linearization of enrollees’
expected year 2 consumption as a function of year 1 observed consumption and predicted year-
to-year trends given observables. The ICR and donut price coefficients vary as a function of
observables as well as the ratio of year 1 consumption to each respective year 1 price.
In order to pool information across all regression sample individuals, we regress year to
year quarterly consumption changes on ICR and donut price changes as well as the deductible
change and “Stark” variables, for high and low-spending enrollees only. The restriction to high
and low-spending enrollees allows us to recover price responses away from budget set kinks.
27The given model was derived assuming that the probability of a given coverage phase being “current”
or “marginal” is fixed and exogenous. The model in Appendix D.2 relaxes these assumptions and the
estimates show that results are unchanged.
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We allow ICR and donut price responses to vary by spending group, as the proportion of
individuals for whom each phase is marginal or current in each period will differ across groups;
we hold all other coefficients fixed across groups. The results are in Table 8.
Table 8: Results of Quarterly ICR and Donut Price Regressions, with Stark Donut Cov-
erage and Deductible Variables – Low- and High-Spending Enrollees, All Years Pooled
Period Price Coef Coef
Q1 ICR .0.053 0.006 ** .0.026 0.008 **
Q1 Donut 0.019 0.007 ** .0.048 0.010 **
Q1 Ded.>Chg .0.049 0.005 ** .0.049 0.005 **
Q1 Stark .0.014 0.009 .0.014 0.009
Q2 ICR .0.045 0.006 ** .0.011 0.009
Q2 Donut 0.026 0.007 ** .0.044 0.013 **
Q2 Ded.>Chg .0.024 0.005 ** .0.024 0.005 **
Q2 Stark 0.002 0.009 0.002 0.009
Q3 ICR .0.043 0.006 ** .0.003 0.009
Q3 Donut 0.012 0.008 .0.083 0.012 **
Q3 Ded.>Chg .0.016 0.006 ** .0.016 0.006 **
Q3 Stark .0.007 0.009 .0.007 0.009
Q4 ICR .0.056 0.008 ** 0.024 0.012 *
Q4 Donut 0.003 0.010 .0.168 0.016 **
Q4 Ded.>Chg .0.012 0.007 .0.012 0.007
Q4 Stark .0.047 0.011 ** .0.047 0.011 **
Notes:>Results>of>quarterly>regressions>of>log>consumption>change>on>log>change>in>ICR>and>donut>prices,>as>
well>as>changes>in>stark>gap>coverage>and>deductible>coverage.>Regression>for>high.>and>low.spending>
enrollees,>with>separate>ICR>and>donut>responses>for>each>spending>group.>N=1,214,548.>"Stark">gap>
coverage>and>deductible>change>response>held>fixed>across>spending>groups.>Superscript>(**)>indicates>
significance>at>the>1%>level;>superscript>(*)>indicates>significance>at>the>5%>level.>>>>>>>>>>>>>>>>
>>>>>>>>
>>>>>>>>
>>>>>>>>
SE SE
All>Years>Pooled>(Pooled>Regression)
Low.Spending>
Enrollee>Response
High.Spending>
Enrollee>Response
The results shown in Table 8 are on the whole consistent with the patterns described above:
low-spending enrollees’ marginal price (ICR price) response is flat over the year and high-
spending enrollees’ marginal price (donut price) response is steeply increasing in magnitude
over the year. Enrollees’ deductible response is decreasing in magnitude over the course of
the year (this is consistent with myopia as enrollees only encounter deductible prices early in
the year). Finally, the response to the “Stark” variable is non-monotonic over the year – it is
largest in Q1 and Q4.28
We use the results of the above regression to infer our structural model parameters. We
28This feature of the results is driven by low-spending enrollees’ non-monotonic response to stark
changes in donut hole coverage – as we see in Appendix Table 8, which compares the results in Table
8 to the same results obtained from separate regressions for the high- and low-spending samples, low-
spending enrollees’ response to the “Stark” variable is negative and significant in Q1 and Q4 (the Q4
response is larger, but not significantly so), while high-spending enrollees’ response to the “Stark”
variable is only significant in Q4. These results are consistent with the low-spending individuals’
response to stark donut hole coverage being driven by salience effects and the high-spending individuals’
response being driven at least in part by myopia.
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pool price response estimates across groups of observations (individual-quarters) whose price
responses are expected to be similar by classifying sample observations by quintile of
(
qit,1
Pi,1
)
∗
exp(aˆt+Xi ∗ δˆt+ uˆit,2), for each price Pi, giving us 25 groups overall – this classification allows
us to define groups of individuals based on similarity in their expected price changes, both
in and outside the regression sample. We then estimate a single ηg for each group g.
29 We
impose a single discount factor β across all sample individuals. Using the expressions including
the parameters η and β in the above Taylor expansions (equations (2) and (3) above), we
use a generalized method of moments (GMM) procedure to estimate our 25 static linear price
response parameters η and our hyperbolic discount parameter β. Equations (2) and (3) require
Pr{CP = ICR}, Pr{MP = ICR}, Pr{CP = Donut}, and Pr{MP = Donut} as inputs –
for the estimates reported, we assumed “perfect foresight” regarding current and marginal
coverage phases, in that we used the actual observed probabilities of each phase being current
or marginal in year 2 for each individual and each quarter.30
Counterfactual simulation requires that we extrapolate the structural parameters for in-
dividuals outside the regression sample (high and low spending enrollees). We extrapolate α,
Ks, and Kd using equations (1), (4), and (5) above. We obtain η and β from the GMM proce-
dure – individuals outside the regression sample falling in group g are assigned the structural
static price response ηˆg and discount factor βˆ. In order to ensure that we extrapolate only to
individuals who are similar to our regression sample, we exclude outliers, defined as individuals
whose exp(Xit ∗ δˆt + uˆit,2) lie below the 1st percentile or above the 99th percentile of the same
metric in the regression sample.
Table 9 displays the mean values for all model parameter estimates for individuals in and
out of the regression sample. At zero prices, our sample is predicted to consume 371 days supply
of drugs per quarter. The average linear price response η = −1.7 implies an average static
price elasticity of −0.13 (evaluated at marginal prices). The quarterly hyperbolic discount
factor β = 0.31 suggests substantial myopia – it implies that, prior to entering their marginal
coverage phase, individuals are more than twice as responsive to the price they currently face
as they are to their marginal price. Finally, on average, eliminating the deductible or adding
29The error term uit,2 is not directly observed, so we use Duan’s smearing technique to scale all trans-
formed coefficients based on the distribution of the regression residuals. We allow for heteroscedasticity
and let the smearing factor vary in demographic variables.
30Of course, enrollees’ expectations could instead be that they will consume in year 2 exactly as they
did in year 1, or they could expect that they will be a random draw from the observed distribution of
consumption among similar individuals based on year 1 consumption. Our estimates are not sensitive
to this assumption – re-estimating the structural parameters using the individual’s actual year 1 phase
probabilities or “rational expectations” phase probabilities generates similar estimates, as discussed
with regard to model fit below. In the rational expectations case, we classify individuals in each year
pair into 100 cells by centiles of year 1 total spending and run the year 2 claims of 200 persons in each
cell through the cost parameters for the plan for each individual in the cell and take the means of the
resulting phase probabilities.
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Table 9: Estimated Structural Model Parameters, All Years Pooled
Description
Structural/
Parameter
Central/
Estimate
Standard/
Error
Days/supply/(P=0) α 370.864 13.746
Myopia β 0.312 0.081
Marginal/price/effect η H1.656 0.146
Deductible/effect Κdeduct H8.833 1.666
Stark/gap/effect Κstark H6.335 2.698
Implied/elasticity ε H0.127 0.011
Notes:/Authors'/calculations./Data/are/shown/only/for/individuals/within/the/1st/to/99th/percentiles/of/
the/distribution/of/the/predicted/trend/in/consumption;/individuals/too/dissimilar/from/the/regression/
sample/in/this/dimension/are/dropped./All/parameters/shown/are/averages/except/for/the/hyperbolic/
discount/factor./Standard/errors/from/nonparametric/bootstrap/of/entire/procedure,/200/iterations.
stark donut hole coverage is predicted to increase consumption per quarter slightly, by 9 and
6 days supply, respectively.
The static price elasticity of −0.13 estimated using this procedure is similar in magnitude
to the literature (see, e.g., Chandra, Gruber, and McKnight (2007)), but is notably smaller
than the static elasticities estimated in Einav, Finkelstein, and Schrimpf (2014) in the Part D
context – they estimate elasticities ranging from -0.3 to -0.5. Their identification strategy infers
price sensitivity from the magnitude of bunching behavior observed at the Part D kink and is
thus focused on a sample we explicitly exclude from our regression analysis – for this reason,
we may not expect to arrive at the same behavioral elasticity. However, as we note below,
the elasticity obtained from our reduced form procedure predicts bunching at the kink well
in a dynamic model. Einav, Finkelstein, and Schrimpf (2014) estimate a weekly exponential
discount factor of 0.96 using variation in timing of enrollees joining Part D plans; if we assume
that this model of discounting is true, it would imply that an individual discounts all future
quarters by an average factor of 0.49 across Q1-Q3, implying significantly more forward-looking
consumption behavior than we estimate.
In order to investigate the behavioral determinants of myopia and salience in the results in
Table 9, we repeated our entire estimation procedure separately for individuals with and with-
out chronic conditions, and for groups of individuals defined by specific chronic conditions.31
This allows us to examine whether individuals taking maintenance drugs on a predictable basis
(as opposed to taking drugs for acute conditions) exhibit the same deviations from rationality
as our overall sample. The results comparing the chronically ill to the non-chronically ill and
31Following Goldman, et al. (2004), we identify seven chronic illnesses – hypercholesterolemia, hy-
pertension, diabetes, gastritis, arthritis, asthma, and affective disorders – using diagnosis codes from
the individuals’ medical claims histories.
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the results for the most popular chronic conditions in our sample (hypercholesterolemia, hy-
pertension, and diabetes) are shown in Appendix Table 9. The estimated hyperbolic discount
factor β is larger in magnitude for the chronically ill (particularly among hypercholesterolemics
and diabetics, who exhibit βs of 0.46 and 0.42, respectively) than for the non-chronically ill,
which is consistent with the chronically ill being more forward-looking. However, the most
striking feature of the table is the consistency in the parameter estimates across groups – even
those with chronic conditions are substantially more sensitive to marginal prices once they
encounter those prices than they are earlier in the year.
Using the model from Section 6 and the estimated structural parameters from Table 9,
we solve for the optimal dynamic consumption path in response to the full nonlinear budget
set for all sample individuals, including those near budget set kinks. Figure 2 displays actual
and predicted consumption (summed over the full year) for individuals throughout the year 1
spending distribution.32 Two versions of the prediction are displayed – the exact quantity pre-
dicted by the regression model, in sample, and the simulated results using the structural model
parameters. Both predictions work quite well for individuals in the regression sample (high
and low-spending individuals) – the structural model under predicts actual year 2 spending by
0.34% on average. Notably, the structural model also replicates consumption for enrollees near
the donut hole threshold quite well – we over predict year 2 spending by 0.18% on average for
this sample. The prediction performs less well as we approach the very high part of the spend-
Figure 2: Actual and Predicted Year 2 Quantity Consumed – Outliers Excluded
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ing distribution and is poor for the small number (1% of the sample) of non-outliers above
32Predicted consumption is simulated consumption throughout the year given actual year 2 prices.
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the top of the “high” spending group (the $5,000 cutoff).33 In the counterfactual simulations
below, individuals above the top “high-spending” cutoff are excluded.34
The absolute and relative distribution of actual and predicted spending are shown in Figure
3.35 Predicted spending is close to actual spending on average, as implied by the comparison
in Figure 2. The left panel of the Figure shows that we slightly underpredict low spending
and overpredict high spending. The right panel shows the distribution of actual and predicted
spending relative to the donut threshold (recall that donut thresholds increase in each year of
the sample). Even though we estimated price sensitivity using only individuals away from the
donut threshold, we are able to replicate bunching at the donut kink quite well. The slight over
prediction of bunching behavior exactly at the kink is due to our assumption of no uncertainty
in the simulation model – allowing for uncertainty would yield some dispersion in excess mass
around the kink, as we observe in the actual spending distribution just to the right of 0.
Figure 3: Distribution of Actual and Predicted Year 2 Spending – Outliers Excluded
The above reduced form and structural analyses showed evidence of imperfectly forward-
looking behavior, which rejects a model of consumers responding rationally to marginal price.
However, the structural model we estimated above, while intuitive, could miss other behavioral
consumption patterns, such as response to an average price as has been found in the empirical
literature on electricity consumption. A comparison of the full structural model (with myopia
33The small 1% sample of non-outliers in the above-$5,000 range accounts for 3% of non-outliers’
spending. In the full sample, those spending above $5,000 account for 6% of enrollees and 18% of
overall spending, as there is a very long tail to the expenditure distribution. Lack of overlap in covariates
between the full range of very high-spending enrollees and our regression sample limits our ability to
extrapolate price responses to that part of the distribution.
34Results are similar whether the perfect foresight approach is used as the model of expectations in
the GMM estimation or whether, alternatively, we use the individual’s year 1 consumption (0.3% error)
or rational expectations (-0.4% error).
35Here, because coverage thresholds are defined based on total drug spending rather than quantity
consumed, we compare actual and predicted spending rather than consumption as in Figure 2.
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and salience terms) to two alternative models – an average price response model and a marginal
price response model – is shown in Table 10. The Table shows that the structural model
(0.18% error) performs better in predicting out-of-sample spending than either the average
price (6.82% error) or marginal price model (10.34% error). Similarly, the mean-squared error
in prediction (MSE) is much smaller for the structural model than either alternative, both in-
and outside the regression sample.
Table 10: Actual and Predicted Year 2 Consumption and Spending – Structural Model,
Average Price Model, and Marginal Price Model
Mean %&diff MSE Mean %&diff MSE Mean %&diff MSE
In-Sample&
(Low/High&Spending&
Enrollees)
1,718.239 1,703.561 -0.85% 996,251 1,755.345 1,799.549 2.52% 1,726,621 1,716.097 1,810.151 5.48% 1,705,993
Out-of-Sample&
(Medium&Spending&
Enrollees)
2,324.124 2,328.278 0.18% 990,186 2,320.353 2,478.690 6.82% 1,816,324 2,316.501 2,555.971 10.34% 1,915,258
All&Spending&Groups 1,972.520 1,965.746 -0.34% 993,706 1,993.213 2,085.467 4.63% 1,764,386 1,963.783 2,117.827 7.84% 1,792,322
Structural&Model&Comparison Average&Price&Model&Comparison Marginal&Price&Model&Comparison
Notes:&Comparison&of&actual&and&simulated&spending,&structural&model&vs.&average&price&model&and&marginal&price&model.&Average&and&marginal&price&models&
estimated&using&quarterly&regressions&of&log&consumption&change&on&year-to-year&change&in&average&price&and&marginal&price,&respectively.&The&same&controls&as&in&
Section&6&are&used&in&the&regressions&and&the&same&smearing&technique&as&in&Section&7&is&employed&to&transform&predictions.&In&each&comparison,&data&are&shown&only&
for&individuals&within&the&1st&to&99th&percentiles&of&the&distribution&of&the&predicted&trend&in&consumption;&individuals&too&&dissimilar&from&the&regression&sample&in&this&
dimension&are&dropped.&Average&and&marginal&prices&determined&by&applying&perfect&foresight&weights&to&&coverage&phase-specific&individual&prices.&
Actual Predicted Actual PredictedActual Predicted
7.2 Counterfactual – Filling in the Donut Hole
We next use the estimated structural parameters to simulate the effect of filling in the donut
hole on total spending for low and high-spending individuals as well as for individuals near
the donut hole kink. We impose that “filling in the donut hole” takes the form of setting the
donut hole price in each plan equal to the ICR price (so that there is no donut kink). For all
individuals with no donut hole coverage or generic only donut hole coverage in year 1 of the
relevant year pair, we also set the “Stark” variable equal to −1, as filling in the donut hole
would entail a stark increase in donut hole coverage.36
Table 11 shows the effect of filling in the donut hole on mean spending, in levels and
percentages. Filling in the donut hole would increase spending by $114 on average, or 6%.
36An important caveat is necessary here. This counterfactual is performed (1) relative to observed
year 2 prices in each sample year pair; and (2) holding all other plan features fixed. Thus, we should
interpret the results as capturing what 2007, 2008, and 2009 consumption would have been if each plan’s
donut hole were filled in, holding enrollment and other features of plan generosity fixed. In order to
determine the effect of changes to the donut hole generosity between now and 2020, one would need to
account for trends in generosity between our sample period and the present, as well as how plans adjust
other plan features in response to the imposed change in donut generosity (which may impact, in turn,
sorting of patients across plans). Without a model to inform supply side responses to the ACA’s donut
policy changes, we leave the more sophisticated counterfactual to future research.
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Table 11: Estimated Effect of Filling in the Donut Hole, Pooled All Years
Estimated)impact)of)
filling)in)the)donut)hole) $114.17 5.81%
Based)on)price)
response)alone) $77.25 3.93%
Additional)effect)of)
price)salience) $36.92 1.88%
Notes:)Authors')calculations.)Data)are)shown)only)for)individuals)within)the)1st)to)99th)
percentiles)of)the)distribution)of)the)predicted)trend)in)consumption;)individuals)too)
dissimilar)from)the)regression)sample)in)this)dimension)are)dropped.)
$77 of this increase is due to the price response (setting the donut price equal to the ICR
price), but $37 (or 32% of the overall effect) comes from what we call the “salience” effect, the
coefficient on the stark increase in donut hole coverage.
Figure 4 shows heterogeneity in the effect of filling in the donut. The left panel shows how
the effect of filling in the donut varies with position in the spending distribution. That is, we
plot the mean increase in spending when we fill in the donut vs. year 1 spending. The price
and salience effects are shown separately. The price effect is monotonically increasing in the
magnitude of spending – individuals whose marginal price is the donut hole price are impacted
more by the price change than individuals who do not hit the donut. Moreover, individuals
who consume more of their prescription drugs while in the donut hole (higher spenders within
the donut-marginal group) are more affected by the price change due to myopia. On the
other hand, the “Stark” or what we called the “salience” effect is present throughout the
spending distribution, so that even low spending individuals are expected to increase spending
in response to the donut hole being filled in. The right panel of Figure 4 plots the mean
increase separately by quarter. As implied by our estimate of the hyperbolic discount factor
β = 0.32, individuals are much less responsive to filling in the donut hole at the beginning of
the year than they are at the end of the year.
8 Discussion
We examine prescription drug consumption in the context of Medicare Part D, an insurance
program in which enrollees are exposed to substantial cost-sharing incentives and in which
nonlinear, complex price schedules are found to lead to additional price responses beyond
those anticipated by the designers.
Our identification strategy allows us to estimate static and dynamic price elasticities using
consumption responses to price variation in multiple regions of the nonlinear budget set. Part
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Figure 4: Heterogeneity in Effect of Filling in the Donut Hole
D enrollees are very unlikely to switch plans between years, giving us a plausibly exogenous
source of identifying variation in the form of year-to-year changes in plan generosity for in-
dividuals already enrolled in Part D plans. Demand models under nonlinear budget sets can
be challenging to estimate; in the absence of enough variation to estimate fully nonparametric
responses, the solution is typically to specify a structural model of consumer optimization. In
order to accommodate multiple behavioral models of consumption suggested by the nonlinear
budget set literature in other contexts, we begin by using linear methods to estimate reduced
form consumption responses to prices throughout the budget set. We focus on individuals
whose marginal prices are highly likely to be in the interior of budget set segments in order
to minimize the impact of nonlinear responses; analysis in the Appendix demonstrates that
our results are robust to further sample restrictions and more complex modeling. We use the
reduced form patterns to estimate a structural model with imperfect forward-looking behavior
and price salience effects, and demonstrate that the model fits the data well; it outperforms
both a fully rational model in which consumers respond to marginal price, as well as an al-
ternative behavioral model in which consumers respond to average price. Notably, the model
performs quite well outside the regression sample, which allows us to simulate consumption
responses to counterfactual price schedules for enrollees throughout the spending distribution,
including those near the donut hole kink.
We find that, while enrollees’ static price elasticities are of a similar magnitude to estimates
in the prior literature, Part D enrollees also exhibit certain behavioral biases in their consump-
tion patterns related to the structure of Part D cost-sharing. In particular, we demonstrate
evidence of imperfectly forward-looking behavior, in that enrollees are much more responsive
to cost-sharing in current periods than in future periods. We also find that enrollees respond
to more salient plan benefit changes, such as addition or removal of entire categories of drugs
from donut hole coverage, beyond how those changes impact enrollees’ actual out-of-pocket
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prices. Given that rational optimization of consumption in a setting such as Part D requires
a complicated calculation with many inputs, these results may not be surprising.
The results described above yield some striking insights into insurance enrollees’ decision-
making, and carry important implications for policy. We find that, all else equal, filling in the
Part D donut hole will increase spending by $114, or 6%, for the average enrollee in our sample.
Over 30% of this effect is due to salience and, accordingly, impacts even relatively low-spending
Part D enrollees. The remainder of the effect occurs primarily at the end of the year, due to
imperfect forward-looking behavior, and falls disproportionately on higher-spending enrollees
who are more likely to enter the donut hole.
Our findings suggest that prescription drug plan designers must carefully account for con-
sumers’ dynamic incentives and understanding of complex price schedules. The welfare impli-
cations of the current Part D plan design will be a function of the price responses documented
here as well as the health impacts of altering drug consumption in response to prices and the
overall program costs in- and outside Part D. We leave these topics for future research. This
paper also developed a useful methodology for analyzing consumption in complex, nonlinear
environments by estimating structural parameters using variation in linear regions of the bud-
get set; we hope to extend the methodology to other applications, such as income taxation, in
future work.
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Appendix
A Price and Instrument Construction
In order to illustrate how our prices and price instruments are calculated, consider the following
example. Suppose that, in 2006, the individual in question takes two drugs monthly, drug X
and drug Y; in 2007, the individual also takes drug Z. In 2006, the individual is enrolled in
plan A; in 2007, she switches to plan B. The retail prices and cost-sharing for Plans A and B,
drugs X, Y, and Z, and years 2006 and 2007 are shown in Appendix Table 1. As we see in the
Table, plan A has coverage of generics (drug Y only) in the donut hole in both years, while
drug B has no donut hole coverage in either year. In general, both retail prices and copays are
different across plans for each drug and across years for each plan-drug.
Appendix Table 1: Retail Prices and Out-of-Pocket Costs for Example Plans and Drugs
Retail'Price Deductible ICR Donut'Hole Catastrophic Retail'Price Deductible ICR Donut'Hole Catastrophic
X 100.00 100.00 30.00 100.00 5.00 110.00 110.00 31.00 110.00 5.50
Y 30.00 30.00 10.00 10.00 2.00 32.00 32.00 12.00 12.00 2.15
Z 150.00 150.00 45.00 150.00 7.50 160.00 160.00 45.00 160.00 8.00
Retail'Price Deductible ICR Donut'Hole Catastrophic Retail'Price Deductible ICR Donut'Hole Catastrophic
X 115.00 115.00 40.00 115.00 5.75 117.00 117.00 40.00 117.00 5.85
Y 25.00 25.00 12.00 25.00 2.00 27.00 27.00 8.00 27.00 2.15
Z 130.00 130.00 50.00 130.00 6.50 130.00 130.00 55.00 130.00 6.50
Drug
2006$Retail$and$Out/of/Pocket$Prices 2007$Retail$and$Out/of/Pocket$Prices
Plan6A,62006 Plan6A,62007
Plan6B,62006 Plan6B,62007
The corresponding phase-year-specific prices and instruments are shown for each drug and
on average across all drugs the individual takes in Appendix Table 2. Recall that our procedure
requires a single price and instrument for each individual-year. For the “actual” prices, we
aggregate the prices in plan A in 2006 using 2006 weights to obtain the 2006 average prices
(e.g., the ICR price in 2006 is $20, the average copay in plan A across drugs X and Y) and we
aggregate the prices in plan B in 2007 using 2007 weights to obtain the 2007 average prices
(e.g., the donut price in 2007 is $91.33, the average copay in plan B across drugs X, Y, and Z).
However, to obtain the instruments, we hold plan choice, retail price, and consumption weights
fixed at 2006 values. Hence, the price instrument in 2006 is the same as the actual price in
2006 in each phase, and the 2007 price instruments differ from the 2006 price instruments
only insofar as plan A’s generosity changed between years 2006 and 2007 holding retail price
fixed. In this example, there is no deductible price change in the instrument for any drug
or on average, the 2006-2007 price change in the ICR equals the change in plan A’s copays
2006-2007, and the donut price only changes for drug Y, the drug with some donut coverage
in plan A.
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Appendix Table 2: Average Prices and Price Instruments for Example Individual
Drug Quantity Deductible ICR Donut4Hole Catastrophic Quantity Deductible ICR Donut4Hole Catastrophic
X 30.00 100.00 30.00 100.00 5.00 30.00 117.00 40.00 117.00 5.85
Y 30.00 30.00 10.00 10.00 2.00 30.00 27.00 8.00 27.00 2.15
Z 0.00 150.00 45.00 150.00 7.50 30.00 130.00 55.00 130.00 6.50
Average 65.00 20.00 55.00 3.50 91.33 34.33 91.33 4.83
Quantity Deductible ICR Donut4Hole Catastrophic Quantity Deductible ICR Donut4Hole Catastrophic
X 30.00 100.00 30.00 100.00 5.00 30.00 100.00 31.00 100.00 5.35
Y 30.00 30.00 10.00 10.00 2.00 30.00 30.00 12.00 12.00 2.15
Z 0.00 150.00 45.00 150.00 7.50 0.00 150.00 45.00 150.00 7.50
Average 65.00 20.00 55.00 3.50 65.00 21.50 56.00 3.75
2006$Phase$Prices$and$Instruments 2007$Phase$Prices$and$Instruments
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B Categorical Donut Hole Coverage
As noted in the text, some of the donut hole coverage variation observed in our sample pertains
to broad categories of drugs and would be easily understood by enrollees, but the sample also
includes many changes that would be difficult for enrollees to translate into prices.
In 2006-7, all donut hole coverage changes are of the former, “stark” variety, in that they
entail plans adding or dropping an entire category or more of drugs to the donut hole coverage;
for example, consider Appendix Table 3a, which shows the count of sample enrollees in 2006-7
by 2006 gap coverage (across rows) and 2007 gap coverage (across columns). The Table shows
that 35,325 individuals were in plans with no donut hole coverage in 2006 and generic donut
hole coverage in 2007 – adding generic coverage implies large average price decreases for the
donut hole of about $10 per 30-day supply. These decreases would be simple for individuals to
understand given knowledge of the prices they face for branded and generic drugs in the ICR
and an understanding of which drugs are generic. In contrast, some plans in 2007-8 and even
more in 2008-9 had slight alterations in their coverage in the donut hole which did not entail
large average price changes and which were not generally easily understandable; see the count
of individuals according to year 1 and year 2 gap coverage in Appendix Table 3b and Appendix
Table 3c. For example, 26,551 enrollees changed from “All Generic” coverage in 2008 to “Many
Generic” coverage in 2009. This did not serve to universally increase average prices in the donut
hole – some plans still decreased copays for covered generics while removing coverage for others
– and the average price increase across plans was small, around $0.56. Further, this type of
coverage change would require a more complicated calculation for individuals to respond to it
than a stark coverage change such as removing/adding coverage for an entire class of drugs – it
is arguably surely easier for enrollees to identify which drugs are branded and generic than to
identify which generic drugs are “Many Generic” or which branded drugs are “Few Brand.”37
37The fact that essentially none of the donut coverage variation in 2008-9 is of this stark form (in
contrast to 2006-7 and 2007-8) may account for the observation in Table 5 that end of year marginal
price responses are somewhat smaller at the end of the year for the 2008-9 sample than for the 2006-7
and 2007-8 samples.
45
Appendix Table 3a: Enrollment by Donut Hole Coverage Changes, 2006-7
Brand& &Gen
Generics,&
Pref.&Brands Generic None
Brand& &
Gen 7,832 18 12,895 6,773
Generic 152 132 31,172 3,093
None 1,851 116 35,325 352,273
2007&Gap&Coverage,&2006@7&Sample
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Notes:&Count&of&sample&enrollees&with&given&gap&coverage&in&2006&and&2007&chosen&
plan(s).&2006&gap&coverage&designated&by&row&value;&2007&gap&coverage&designated&
by&column&value.
Appendix Table 3b: Enrollment by Donut Hole Coverage Changes, 2007-8
Some%
Generics
All%Generics%
and%Some%
Brands
All%Preferred%
Generics All%Generics None
Brand%&%
Gen 89 1 666 7,556 7,746
Generics,%
Pref.%
Brands
1 0 392 7 136
Generic 27,909 19 62,653 52,386 24,629
None 218 9 2,690 5,211 934,364
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%%%
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Notes:%Count%of%sample%enrollees%with%given%gap%coverage%in%2007%and%2008%chosen%plan(s).%2007%gap%
coverage%designated%by%row%value;%2008%gap%coverage%designated%by%column%value.
Appendix Table 3c: Enrollment by Donut Hole Coverage Changes, 2008-9
Some%
Generics All%Generics
All%Generics%
and%Few%
Brands
Many%
Generics
Many%
Generics%and%
Few%Brands None
Some%
Generics 985 48 0 25,710 0 1,651
All%
Preferred%
Generics
136 252 14 55,588 384 6,336
All%
Generics 701 30,506 44 26,551 0 7,230
All%
Generics%
and%Some%
Brands
28 0 0 0 0 13
None 3,099 775 55 2,452 2 966,640
2009%Gap%Coverage,%2008G9%Sample%%%%%
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e%
%%%
%%%
%
Notes:%Count%of%sample%enrollees%with%given%gap%coverage%in%2008%and%2009%chosen%plan(s).%2008%gap%coverage%
designated%by%row%value;%2009%gap%coverage%designated%by%column%value.
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In incorporating donut coverage variation in our sample into our regression analysis, we
focus on the sort of “stark” variation observed primarily in 2006-7 and 2007-8, as it maps
more clearly into price changes and is more likely to be understood by enrollees. Sensitivity
analysis where we include separate coverage change variables for “stark” coverage changes and
for “non-stark” coverage changes leave the included variables unchanged – the “non-stark”
variables capturing subtle donut hole price changes are not statistically significant.
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C Taylor Expansion in Structural Model
Letting zy be the vector of year y prices, we linearize the specification around z1. We use the
following Taylor expansion:
qit,2(z2) = f(z2) = qit,1 ∗ exp
(
at +Xit ∗ δt + bit,ICR ∗
(
log(Pi,ICR,2)
log(Pi,ICR,1)
))
∗ qit,1 ∗ exp
(
bit,Donut ∗
(
log(Pi,Donut,2)
log(Pi,Donut,2)
))
∗ qit,1 ∗ exp(θDed,t ∗ dedchgi + θstark,t ∗ starki
∗ qit,1 ∗ exp(uit,2)
∼= f(z1) +
(
∂f(z1)
∂PICR
)
(Pi,ICR,2 − Pi,ICR,1) +
(
∂f(z1)
∂PDon
)
(Pi,Don,2 − Pi,Don,1)
+
(
∂f(z1)
∂dedchg
)
dedchgi +
(
∂f(z1)
∂stark
)
starki.
The Taylor expansion yields the following form for year 2 consumption:
qit,2(z2) ∼= qit,1 ∗ exp(at +Xit ∗ δt + uit,2)
+ qit,1 ∗ exp(at +Xit ∗ δt + uit,2) ∗
(
Pi,ICR,2 − Pi,ICR,1
Pi,ICR,1
)
∗ bit,ICR
+ qit,1 ∗ exp(at +Xit ∗ δt + uit,2) ∗
(
Pi,Don,2 − Pi,Don,1
Pi,Don,1
)
∗ bit,Don
+ qit,1 ∗ exp(at +Xit ∗ δt + uit,2) ∗ (dedchgi ∗ θDed,t + starki ∗ θStark,t)
= qit,1 ∗ exp(at +Xit ∗ δt + uit,2)(1− bit,ICR − bit,Don)
+
(
qi,1
Pi,ICR,1
)
∗ exp(at +Xit ∗ δt + uit,2) ∗ Pi,ICR,2 ∗ bit,ICR
+
(
qi,1
Pi,Don,1
)
∗ exp(at +Xit ∗ δt + uit,2) ∗ Pi,Don,2 ∗ bit,Don
+ qit,1 ∗ exp(at +Xit ∗ δt + uit,2) ∗ (dedchgi ∗ θDed,t + starki ∗ θStark,t)
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D Robustness
In this Section, we explore the sensitivity of our methodology to the assumptions that enrollees
in our estimation sample have no uncertainty about marginal coverage phase and that current
and marginal coverage phase assignments are fixed and exogenous with respect to out-of-pocket
prices.
D.1 Limited Uncertainty about Marginal Coverage Phase
In the regression estimations used to obtain our structural parameter estimates, we noted
that our restriction to “low” and “high” spending individuals does not guarantee that those
individuals have no uncertainty about marginal coverage phase. “Low” spending individuals
cross the donut threshold in year 2 3% of the time; “high” spending individuals do not cross
the donut threshold in year 2 14% of the time. In this Section, we investigate sensitivity to
classification of the low and high-spending individuals to determine whether uncertainty or
switching behavior is likely to bias our results. In order to perform this check, we first regress
an indicator for ending the year in the “appropriate” (ICR for low-spending individuals, donut
for high-spending individuals) coverage phase on all demographic and spending controls. We
reduce the “error”, as defined by the individual ending the year on the wrong side of the donut
threshold, by 50% and by 25% by restricting the sample based on the predicted probability
of ending in the appropriate marginal coverage phase, and display the results of the quarterly
regression for these samples.
The results are shown in Appendix Table 4. Of the 48 coefficients estimated, two are
statistically significantly different than in the baseline sample – the deductible change response
is larger in magnitude in the restricted samples, significantly so in the 25% restricted sample
for Q2, and the Q2 ICR response by low-spending individuals is significantly smaller in the 50%
restricted sample. Otherwise, the point estimates are similar in magnitude and exhibit similar
dynamic patterns – the marginal price coefficients in the 25% restricted sample are slightly
smaller in magnitude, while the marginal price coefficients in the 50% restricted sample are
sometimes smaller, sometimes larger, than in the baseline sample.
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Appendix Table 4: Results of Quarterly ICR and Donut Price Regressions, with Stark
Donut Coverage and Deductible Variables – High- and Low-Spending Enrollees, Pooled
Years, Baseline and Restricted Samples
Period Price Coef Coef Coef Coef Coef Coef
Q1 ICR .0.056 0.005 ** .0.022 0.007 ** .0.056 0.006 ** .0.019 0.009 * .0.049 0.007 ** .0.023 0.013
Q1 Donut 0.030 0.007 ** .0.040 0.009 ** 0.027 0.007 ** .0.032 0.011 ** 0.021 0.009 * .0.031 0.017
Q1 Ded.=Chg .0.035 0.005 ** .0.035 0.005 ** .0.046 0.006 ** .0.046 0.006 ** .0.047 0.007 ** .0.047 0.007 **
Q1 Stark .0.015 0.006 * .0.015 0.006 * .0.026 0.012 * .0.026 0.012 * .0.009 0.015 .0.009 0.015
Q2 ICR .0.051 0.005 ** .0.007 0.007 .0.044 0.006 ** .0.002 0.009 .0.029 0.007 ** ! 0.011 0.015
Q2 Donut 0.029 0.007 ** .0.051 0.015 ** 0.030 0.008 ** .0.029 0.016 0.025 0.009 ** .0.029 0.023
Q2 Ded.=Chg .0.009 0.005 .0.009 0.005 .0.027 0.006 ** ! .0.027 0.006 ** ! .0.014 0.007 * .0.014 0.007 *
Q2 Stark 0.001 0.008 0.001 0.008 0.010 0.011 0.010 0.011 0.011 0.015 0.011 0.015
Q3 ICR .0.048 0.005 ** 0.002 0.008 .0.038 0.006 ** 0.016 0.010 .0.036 0.007 ** 0.008 0.016
Q3 Donut 0.014 0.007 .0.091 0.014 ** 0.011 0.008 .0.075 0.015 ** 0.001 0.010 .0.085 0.020 **
Q3 Ded.=Chg .0.008 0.005 .0.008 0.005 .0.016 0.006 ** .0.016 0.006 ** .0.018 0.008 * .0.018 0.008 *
Q3 Stark 0.000 0.007 0.000 0.007 .0.005 0.011 .0.005 0.011 .0.014 0.014 .0.014 0.014
Q4 ICR .0.062 0.007 ** 0.032 0.010 ** .0.054 0.008 ** 0.050 0.013 ** .0.052 0.009 ** 0.050 0.019 **
Q4 Donut 0.006 0.010 .0.183 0.017 ** 0.007 0.011 .0.172 0.026 ** 0.007 0.012 .0.184 0.039 **
Q4 Ded.=Chg .0.004 0.005 .0.004 0.005 .0.015 0.007 * .0.015 0.007 * .0.011 0.008 .0.011 0.008
Q4 Stark .0.041 0.009 ** .0.041 0.009 ** .0.058 0.014 ** .0.058 0.014 ** .0.071 0.017 ** .0.071 0.017 **
Notes:=Results=of=quarterly=regressions=of=log=consumption=change=on=log=change=in=ICR=and=donut=prices,=as=well=as=changes=in=stark=gap=coverage=and=
deductible=coverage,=main=regression=estimation=sample=("Baseline")=vs.=more=restricted=samples.=The=sample=denoted="Error=Reduce=25%"=uses=the=results=of=
a=regression=of=an=indicator=for=ending=the=year=in=the=appropriate=coverage=phase=on=year=1=demographic=and=spending=variables=to=reduce=the="Error"=rate=
(defined=as=ending=the=year=on=the=wrong=side=of=the=donut=threshold)=by=X%.=Superscript=(**)=indicates=significance=at=the=1%=level;=superscript=(*)=indicates=
significance=at=the=5%=level.=======
=======
=======
Pred=(Error=Reduce=25%)=[N=988,123]
SE SE SE SE SE SE
Pred=(Error=Reduce=50%)=[N=700,114]
Low.Spending=
Enrollee=Response
High.Spending=
Enrollee=Response
Low.Spending=
Enrollee=Response
High.Spending=
Enrollee=Response
Baseline=Thresholds=[N=1,214,548]
Low.Spending=
Enrollee=Response
High.Spending=
Enrollee=Response
On balance, the results of this specification check indicate that our results are not sensitive
to further restriction of our sample to reduce marginal coverage phase switching behavior.
D.2 Allowing Current and Marginal Coverage Phase to Respond to Out-
of-Pocket Prices
Recall the derivation of the dynamic structural model in Section 6.1. The solution for optimal
consumption shown in equation (2) assumed that individuals end each period in the interior
of a coverage phase (i.e., no bunching), and also that current and marginal coverage phases
do not respond to out-of-pocket prices (i.e., no switching). The restriction of the estimation
sample to individuals ending year 1 well away from the donut threshold is intended to limit
violations of these assumptions, and the evidence in Section D.1 above provides reassurance
on this point. In this Section, we estimate a richer model that allows for both bunching and
switching, and find ultimately that our results are unaffected.
Consider a more general version of the model in Section 6.1, where consumers choose
consumption in each period according to the following value functions:
VT (XT , AT ) = WT (XT , AT ) = maxqu(q, AT )− EOOP (XT , q)
Vt(Xt, At) = maxqu(q, At)− EOOP (Xt, q) + β
∫
Wt+1(Xt + q ∗R,At+1)dF (At+1) ∀t < T
Wt(Xt, At) = maxqu(q, At)− EOOP (Xt, q) +
∫
Wt+1(Xt + q ∗R,At+1)dF (At+1).
Both Vt and Wt are continuous everywhere and differentiable everywhere except Xt = X¯. At
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denotes a set of parameters impacting the utility function in period t (e.g., At could scale
marginal utility in period t). Denote ut(q) = u(q, At). We allow for uncertainty regarding
prescription drug needs in future periods using this term. For the sake of exposition, we begin
by assuming that there is a single coverage phase kink, a convex kink at X¯ where the out-
of-pocket price changes from p1 to p2 > p1. If an individual has spent Xt on drugs up until
period t and purchases qt units in period t, her period t out-of-pocket expenditure will be:
EOOP (Xt, qt) =

p1 ∗ qt if Xt +R ∗ qt ≤ X¯
p1 ∗ X¯−XtR + p2 ∗
(
qt − X¯−XtR
)
if Xt +R ∗ qt > X¯ and Xt ≤ X¯
p2 ∗ qt if Xt > X¯.
We will then generalize the solution to allow for deductible and catastrophic coverage phases
in addition to the ICR and donut.
Consider first period T ; at the beginning of period T , all uncertainty regarding prescription
drug needs for the year will have been resolved. If XT ≥ X¯, then the consumer faces a linear
price of p2 per unit and optimal consumption will equal q
∗
T = u
′−1
T (p2). If XT < X¯, then the
solution will be the piecewise nonlinear budget set solution as in equation (1):
q∗T (XT ) =

u
′−1
T (p1) if u
′
T
(
X¯−XT
R
)
≤ p1 and XT ≤ X¯
X¯−XT
R if p1 < u
′
T
(
X¯−XT
R
)
≤ p2 and XT ≤ X¯
u
′−1
T (p2) if u
′
T
(
X¯−XT
R
)
> p2 or XT > X¯.
Note that there is some probability of bunching in the final period if XT < X¯. Denote
q˜ct = u
′−1
t (pc).
Next consider period T − 1. If XT−1 ≥ X¯, then the consumer faces a linear price p2 in
the remaining period and W ′T (X,AT ) = 0 for all AT . The solution will be q
∗
T−1 = q˜
2
T−1. If
XT−1 < X¯, then we must consider three cases. If the individual consumes past the coverage
threshold in period T − 1, then we again have W ′T (X,AT ) = 0 for all AT and the solution
will be q∗T−1 = q˜
2
T−1. If the individual bunches in period T − 1, then mechanically q∗T−1 =
(X¯ −XT−1)/R. Finally, if the individual remains in the ICR in period T − 1, then we must
in turn consider three possibilities for period T consumption behavior – the case where the
individual remains in the ICR in period T as well: {stayT }; the case where the individual
bunches in period T : {bunchT }; and the case where the individual crosses the threshold in
period T : {crossT }. The objective function conditional on remaining in the ICR in period
T − 1 is:
maxquT−1(q)− p1 ∗ q
+β ∗ Pr{stayT } ∗E(WT (XT−1, AT )|stayT )
+β ∗ Pr{bunchT } ∗E(WT (XT−1, AT )|bunchT )
+β ∗ Pr{crossT } ∗E(WT (XT−1, AT )|crossT ).
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Substituting in the results from above, we have:
maxquT−1(q)− p1 ∗ q
+ Pr{stayT } ∗ β ∗
∫ (
uT (q˜
1
T )− p1 ∗ q˜1T
)
dF (AT )
+ Pr{bunchT } ∗ β ∗
∫ (
uT
(
X¯ −XT−1
R
− q
)
− p1 ∗
(
X¯ −XT−1
R
− q
))
dF (AT )
+ Pr{crossT } ∗ β ∗
∫ (
uT (q˜
2
T )− p1 ∗
(
X¯ −XT−1
R
− q
)
− p2 ∗
(
q˜2T −
X¯ −XT−1
R
+ q
))
dF (AT ).
By the envelope theorem, this implies the following first-order condition:
u′T−1(q) = p1 + Pr{bunchT } ∗ β ∗
∫ (
u′T
(
X¯ −XT−1
R
− q
)
− p1
)
dF (AT )
+Pr{crossT } ∗ β ∗ (p2 − p1)
= (1− β ∗ Pr{crossT }) ∗ p1 + Pr{crossT } ∗ β ∗ p2
+β ∗ Pr{bunchT } ∗E
(
u′T
(
X¯ −XT−1
R
− q
)
− p1
)
.
Let qST−1(XT−1) be the unique solution to the above equation. To determine the region of
AT−1 for which the individual will remain in the ICR (stayT−1), bunch at the donut kink
(bunchT−1), or cross into the donut hole (crossT−1), we consider the limits of the first-order
condition as q approaches (X¯ − XT−1)/R from the left-hand side and right-hand side. The
limit of the period T −1 first-order condition above as we approach the kink from the left-hand
side is:
u′T−1(q)− (1− β) ∗ p1 − β ∗ p2,
as the probability of entering the donut in period T goes to one (and, accordingly, as Pr{bunchT }
goes to zero). The limit of the period T − 1 first-order condition as we approach the kink from
the right-hand side is simply:
u′T−1(q)− p2
since W ′T = 0 for all q such that XT−1 +R∗q > X¯. Then optimal consumption in period T −1
will be:
q∗T−1(XT−1) =

qST−1(XT−1) if u
′
T−1
(
X¯−XT−1
R
)
≤ (1− β) ∗ p1 + β ∗ p2 and XT−1 ≤ X¯
X¯−XT−1
R if (1− β) ∗ p1 + β ∗ p2 < u′T
(
X¯−XT−1
R
)
≤ p2 and XT−1 ≤ X¯
q˜2T−1 if u
′
T
(
X¯−XT−1
R
)
> p2 or XT−1 > X¯
.
This analysis yields the following general solution.
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Theorem 1 For any period t < T , the optimal consumption path will be:
q∗t (Xt) =

qSt (Xt) if Xt ≤ X¯ and u′t
(
X¯−Xt
R
)
≤ (1− β) ∗ p1 + β ∗ p2
X¯−Xt
R if Xt ≤ X¯ and (1− β) ∗ p1 + β ∗ p2 < u′t
(
X¯−Xt
R
)
≤ p2
q˜2t if Xt > X¯ or u
′
t
(
X¯−Xt
R
)
> p2
.
with qSt (Xt) defined by
u′t(q
S
t (Xt)) =
(
1− β ∗
T∑
i=t+1
Pr{crossi|t}
)
∗ p1 + β ∗
T∑
i=t+1
Pr{crossi|t} ∗ p2
+β ∗
T∑
i=t+1
Pr{bunchi|t} ∗E
(
u′i
(
X¯ −Xi−1
R
− qi−1
)
− p1|t
)
.
Proof 1 We prove this result by induction. Suppose that the result holds in t+1, and consider
the optimal consumption for period t. If Xt ≥ X¯, then as usual the consumer faces a linear
price p2 in all remaining periods and W
′
t+1(X,At+1) = 0 for all At+1; the solution will be
q∗t = u
′−1
t (p2) = q˜
2
t . If Xt < X¯, then we must consider three cases. If the individual consumes
past the coverage threshold in period t, then we again have W ′t+1(X,At+1) = 0 for all At+1
and the solution will be q∗t = q˜2t . If the individual bunches in period t, then mechanically
q∗t = (X¯ − Xt)/R. If, however, the individual remains in the ICR in period t, then we must
consider the three potential outcomes in period t+ 1: {stayt+1}, {buncht+1}, and {crosst+1}.
The objective function is:
maxqut(q)− p1 ∗ q
+β ∗ Pr{stayt+1|t} ∗E(Wt+1(Xt +R ∗ q, At+1)|stayt+1)
+β ∗ Pr{buncht+1|t} ∗E(Wt+1(Xt +R ∗ q, At+1)|buncht+1)
+β ∗ Pr{crosst+1|t} ∗E(Wt+1(Xt +R ∗ q, At+1)|crosst+1).
Again applying the envelope theorem, the first-order condition for this objective function is:
u′t(q) = p1
− β ∗ Pr{stayt+1|t} ∗E(W ′t+1(Xt +R ∗ q, At+1)|stayt+1)
− β ∗ Pr{buncht+1|t} ∗E(W ′t+1(Xt +R ∗ q, At+1)|buncht+1)
− β ∗ Pr{crosst+1|t} ∗E(W ′t+1(Xt +R ∗ q, At+1)|crosst+1).
(8)
If the individual either crosses or bunches in period t + 1, then E(W ′i (Xi, Ai)|t) = 0 for all
i > t+ 1. Accordingly, if {crosst+1} = 1, then
E(W ′t+1(Xt +R ∗ q, At+1)|crosst+1) = −(p2 − p1) (9)
and if {buncht+1} = 1, then
E(W ′t+1(Xt +R ∗ q, At+1)|buncht+1) = −E
(
u′t+1
(
X¯ −Xt+1
R
)
|t
)
+ p1. (10)
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Finally, if {stayt+1} = 1, then by the inductive hypothesis we have
E(W ′t+1(Xt +R ∗ q, At+1)|t+ 1, stayt+1)
= E
(∑T
i=t+2 Pr{bunchi|t+ 1, stayt+1} ∗E
(
−u′i
(
X¯−Xi
R
)
+ p1|t+ 1, stayt+1
)
|t
)
+E
(∑T
i=t+2 Pr{crossi|t+ 1, stayt+1} ∗ (p1 − p2)|t
)
.
(11)
Substituting equations (9), (10), and (11) into equation (8), and applying the law of iterated
expectations, we obtain
u′t(q) = p1
− β ∗E
(∑T
i=t+2 Pr{bunchi} ∗
(
−u′i
(
X¯−Xi
R
)
+ p1
)
|t
)
− β ∗E
(∑T
i=t+2 Pr{crossi} ∗ (p1 − p2)|t
)
+ β ∗ Pr{buncht+1|t} ∗
(
E
(
u′t+1
(
X¯−Xt+1
R
)
|t
)
− p1
)
+ β ∗ Pr{crosst+1|t} ∗ (p2 − p1).
(12)
The second and third lines follow from the fact that Pr{stayt+1|t} ∗ Pr{bunchi|stayt+1, t} =
Pr{stayt+1 ∩ bunchi|t} = Pr{stayt+1|bunchi, t} ∗ Pr{bunchi|t} = Pr{bunchi|t} and similarly
Pr{stayt+1|t}∗Pr{crossi|stayt+1, t} = Pr{crossi|t} for all i > t+1 (by definition, one cannot
cross or bunch in any period unless they have “stayed” in all previous periods). This expression
simplifies to
u′t(q) = p1
+ β ∗E
(∑T
i=t+1 Pr{bunchi|t} ∗
(
u′i
(
X¯−Xi
R
)
− p1
)
|t
)
+ β ∗∑Ti=t+1 Pr{crossi|t} ∗ (p2 − p1).
This implies that the optimal consumption level if the individual remains in the ICR in period
t will be qSt (Xt) such that
u′t(q
S
t (Xt)) =
(
1− β ∗
T∑
i=t+1
Pr{crossi|t}
)
∗ p1 + β ∗
T∑
i=t+1
Pr{crossi|t} ∗ p2
+β ∗
T∑
i=t+1
Pr{bunchi|t} ∗E
(
u′i
(
X¯ −Xi−1
R
− qi−1
)
− p1|t
)
which, in turn, implies the full solution38
q∗t (Xt) =

qSt (Xt) if Xt ≤ X¯ and u′t
(
X¯−Xt
R
)
≤ (1− β) ∗ p1 + β ∗ p2
X¯−Xt
R if Xt ≤ X¯ and (1− β) ∗ p1 + β ∗ p2 < u′t
(
X¯−Xt
R
)
≤ p2
q˜2t if Xt > X¯ or u
′
t
(
X¯−Xt
R
)
> p2
.
Thus completing the proof.
38We apply the same reasoning as in the above analysis for T − 1 to define the ranges of u′t(.) such
that the individual will choose to stay, bunch, or cross in period t.
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We now describe how we generalize this model to allow for the deductible and catastrophic
coverage phases, estimate the richer model on our sample of low- and high-spending individ-
uals, and use the resulting parameters to simulate consumption for the full sample (including
individuals near the donut hole kink) as in Section 7. While our model in principle can allow
for bunching, in practice the probability of bunching in the sample of low- and high-spending
individuals is so low (< 0.1% according any model of expectations) that we omit this term.39
We then have
q∗t (Xt) =
 q
S
t (Xt) if Xt ≤ X¯ and u′t
(
X¯−Xt
R
)
≤ (1− β) ∗ p1 + β ∗ p2
q˜2t if Xt > X¯ or u
′
t
(
X¯−Xt
R
)
> p2
with qSt (Xt) such that
u′t(q
S
t (Xt)) =
(
1− β ∗
T∑
i=t+1
Pr{crossi|t}
)
∗ p1 + β ∗
T∑
i=t+1
Pr{crossi|t} ∗ p2.
It is useful to rewrite this solution such that marginal utility is equal to the appropriate virtual
price given the coverage phase in which the individual ends the current period and the year:
u′ (q∗t ) = Pr{ICRt} [(1− β ∗ Pr{donutT |ICRt}) ∗ p1 + β ∗ Pr{donutT |ICRt} ∗ p2]
+Pr{donutt} ∗ p2
where, in this notation, Pr{ct} is the probability that the individual ends period t in coverage
phase c. Again, all bunching terms are omitted. The deductible and catastrophic phases
are conceptually straightforward to incorporate into our model because they are convex kinks
and thus do not permit bunching. Repeating the above model derivation allowing for these
additional coverage phases yields:
u′ (q∗t ) = Pr{dedt} ∗ (1− β ∗ (Pr{ICRT |dedt}+ Pr{donT |dedt}+ Pr{catT |dedt})) ∗ p0
+ Pr{dedt} ∗ β ∗ [Pr{ICRT |dedt} ∗ p1 + Pr{donT |dedt} ∗ p2 + Pr{catT |dedt} ∗ p3]
+ Pr{ICRt} ∗ (1− β ∗ (Pr{donT |ICRt}+ Pr{catT |ICRt})) ∗ p1
+ Pr{ICRt} ∗ β ∗ [Pr{donT |ICRt} ∗ p2 + Pr{catT |ICRt} ∗ p3]
+ Pr{dont} ∗ ((1− β ∗ Pr{catT |dont}) ∗ p2 + β ∗ Pr{catT |dont} ∗ p3)
+ Pr{catt} ∗ p3.
This expression simplifies to our result from equation (2): q∗ = u′−1 ((1− β) ∗ CP + β ∗MP ).
However, it provides greater detail on where each individual price enters the optimal consump-
tion function. Suppose, as in our structural modeling exercise above, that u(q) is quadratic in
39The estimation strategy below can be modified to allow for bunching by estimating an auxiliary
model of bunching as a function of prices.
55
q. We can then rearrange and differentiate to obtain:
∂q∗t
∂p1
= η ∗ ∂Pr{dedt}∗(1−β∗(Pr{ICRT |dedt}+Pr{donT |dedt}+Pr{catT |dedt}))∂p1 ∗ p0
+ η ∗ β ∗
[
∂Pr{dedt∩ICRT }
∂p1
∗ p1 + ∂Pr{dedt∩donT }∂p1 ∗ p2 +
∂Pr{dedt∩catT }
∂p1
∗ p3
]
+ η ∗
[
∂Pr{ICRt}
∂p1
− β ∗
(
∂Pr{ICRt∩donT }
∂p1
+ ∂Pr{ICRt∩catT }∂p1
)]
∗ p1
+ η ∗ β ∗
[
∂Pr{ICRt∩donT }
∂p1
∗ p2 + ∂Pr{ICRt∩catT }∂p1 ∗ p3
]
+ η ∗
(
∂Pr{dont}
∂p1
− β ∗ ∂Pr{dont∩catT }∂p1
)
∗ p2 + η ∗ β ∗ ∂Pr{dont∩catT }∂p1 ∗ p3
+ η ∗ ∂Pr{catt}∂p1 ∗ p3
+ η ∗ β ∗ Pr{dedt ∩ ICRT }
+ η ∗ Pr{ICRt} ∗ (1− β ∗ (Pr{donT |ICRt}+ Pr{catT |ICRt}))
(13)
and similarly for ∂q∗t /∂p2. The key distinction between this specification and the one estimated
in Section 7 is that the current, richer specification allows for endogenous coverage phase
switching, as each coverage phase probability term is allowed to respond endogenously to
coverage phase prices.
In order to estimate this richer model, we use the following procedure: (1) we estimate
how each coverage phase probability term (e.g., Pr{ICRT |dedt}, Pr{dont}, etc.) responds
to p1 and p2. We use the same exact regression specification and controls as in Section 6,
but use the relevant probability term as the left-hand-side variable. The probability term is
calculated assuming perfect foresight as our model of expectations, as in Section 7. Next, we
(2) perform the GMM estimation as in Section 7, but instead of using equations (4) and (5) in
the GMM objective function directly, we replace the left-hand sides of equations (4) and (5)
with equation (13) and its analog for the donut price. We use this richer specification as the
GMM objective function to recover η and β. Finally (3), using the new estimates of η and β,
we simulate consumption for all sample individuals and compare to observed consumption.40
The results of this procedure are overall quite similar to the results when we do not allow
for endogenous coverage phase switching. The estimates of η and β are not statistically sig-
nificantly different from the baseline estimates in Section 7 (the richer model yields β = 0.313
and η¯ = −1.77, whereas the simpler model estimates were β = 0.312 (SE=0.08) and η¯ = −1.66
(SE=0.15)). The comparison of actual to simulated spending are shown, for each model, in
Appendix Table 5. If anything, the simulation of consumption both in- and outside the regres-
sion sample performs slightly worse than the simpler approach – the mean squared error with
the richer specification is 1% higher in the regression sample, and 5% higher in the sample of
individuals near the donut threshold.
40Note that, whether we use the simple GMM procedure in Section 7 or the richer GMM procedure
outlined here to recover η and β, the simulations of consumption in- and outside the regression sample
always allow for bunching and switching behavior.
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Appendix Table 5: Comparison of Actual to Predicted Spending – Basic Structural
Model and Richer Specification
Mean %&diff MSE Mean %&diff MSE
In-Sample&
(Low/High&
Spending&
Enrollees)
1,718.239 1,703.561 -0.85% 996,251 1,718.239 1,694.167 -1.40% 1,006,810
Out-of-
Sample&
(Medium&
Spending&
Enrollees)
2,324.124 2,328.278 0.18% 990,186 2,324.124 2,316.333 -0.34% 1,035,317
All&Spending&
Groups 1,972.520 1,965.746 -0.34% 993,706 1,972.520 1,955.281 -0.87% 1,018,774
Notes:&Comparison&of&actual&and&simulated&spending,&baseline&structural&model&from&Section&7&vs.&richer&
structural&model&from&Appendix&D.2.&In&each&&comparison,&data&are&shown&only&for&individuals&within&the&1st&
to&99th&percentiles&of&the&distribution&of&the&predicted&trend&in&consumption;&individuals&too&&dissimilar&from&
the&regression&sample&in&this&dimension&are&dropped.&
Baseline&Structural&Model&Comparison Richer&Structural&Model&Comparison&&&
Actual Predicted Actual Predicted
Overall, this analysis demonstrates that the simple approach, which restricts the sample
to individuals on the linear portions of the budget set and ignores bunching and switching
behavior, performs as well as more complex nonlinear models of consumption.
57
E Additional Tables
Appendix Table 6: Results of Full Year ICR (and Donut) Price Regressions, with Stark
Donut Coverage and Deductible Variables – All Enrollees
Price Coef Coef
ICR +0.078 0.006 ** +0.079 0.006 **
Donut 0.021 0.009 *
Ded.:Chg +0.039 0.006 ** +0.040 0.006 **
Stark +0.043 0.008 ** +0.037 0.008 **
Notes::Results:of:full:year:regressions:of:log:consumption:change:on:log:change:
in:ICR:and:donut:prices,:as:well:as:changes:in:stark:gap:coverage:and:deductible:
coverage.:Full:sample:of:enrollees:included.:Superscript:(**):indicates:significance:
at:the:1%:level;:superscript:(*):indicates:significance:at:the:5%:level.:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
SE SE
Full:Sample,:All:Years:Pooled
Including:Donut: Excluding:Donut
Appendix Table 7: Results of Full Year ICR (and Donut) Price Regressions, with Stark
Donut Coverage and Deductible Variables – All Enrollees vs. Non-Switchers Only
Price Coef Coef
ICR +0.078 0.006 ** +0.077 0.006 **
Donut 0.021 0.009 * 0.022 0.009 *
Ded.:Chg +0.039 0.006 ** +0.036 0.005 **
Stark +0.043 0.008 ** +0.029 0.008 **
Notes::Results:of:full:year:regressions:of:log:consumption:change:on:log:change:
in:ICR:and:donut:prices,:as:well:as:changes:in:stark:gap:coverage:and:deductible:
coverage.:Full:sample:of:enrollees:included.:Superscript:(**):indicates:significance:
at:the:1%:level;:superscript:(*):indicates:significance:at:the:5%:level.:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
:::::::
SE SE
Full:Sample,:All:Years:Pooled
All
N=2,707,315
Non+Switchers
N=2,435,952
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Appendix Table 8: Results of Quarterly ICR and Donut Price Regressions, with Stark
Donut Coverage and Deductible Variables – High- and Low-Spending Enrollees, Pooled
All Years, Pooled vs. Separate Regressions
Period Price Coef Coef Coef Coef
Q1 ICR .0.054 0.006 ** .0.027 0.008 ** .0.062 0.006 ** .0.026 0.008 **
Q1 Donut 0.023 0.007 ** .0.045 0.010 ** 0.035 0.008 ** .0.061 0.012 **
Q1 Ded.=Chg .0.048 0.006 ** .0.048 0.006 ** .0.033 0.005 ** .0.042 0.006 **
Q1 Stark .0.016 0.009 .0.016 0.009 .0.025 0.007 ** .0.003 0.008
Q2 ICR .0.046 0.006 ** .0.010 0.009 .0.054 0.006 ** .0.016 0.008
Q2 Donut 0.029 0.007 ** .0.037 0.014 ** 0.034 0.007 ** .0.088 0.014 **
Q2 Ded.=Chg .0.024 0.005 ** .0.024 0.005 ** .0.014 0.006 * .0.004 0.007
Q2 Stark 0.000 0.009 0.000 0.009 .0.003 0.008 0.006 0.011
Q3 ICR .0.045 0.006 ** .0.003 0.009 .0.047 0.006 ** .0.015 0.009
Q3 Donut 0.015 0.008 .0.076 0.013 ** 0.010 0.008 .0.109 0.015 **
Q3 Ded.=Chg .0.016 0.006 ** .0.016 0.006 ** .0.011 0.006 .0.004 0.008
Q3 Stark .0.008 0.009 .0.008 0.009 0.006 0.008 .0.011 0.010
Q4 ICR .0.060 0.008 ** 0.022 0.012 .0.060 0.008 ** 0.009 0.011
Q4 Donut 0.008 0.010 .0.162 0.017 ** 0.001 0.010 .0.204 0.020 **
Q4 Ded.=Chg .0.012 0.007 .0.012 0.007 .0.005 0.006 .0.005 0.010
Q4 Stark .0.047 0.011 ** .0.047 0.011 ** .0.046 0.010 ** .0.030 0.013 *
Pooled=Regression Separate=Regressions
Low.Spending=
Enrollee=Response
High.Spending=
Enrollee=Response
SE SE
Low.Spending=
Enrollee=Response
High.Spending=
Enrollee=Response
SE SE
Appendix Table 9: Estimated Structural Model Parameters, Pooled All Years – By
Chronic Condition
Description
Structural/
Parameter
Mean/
Estimate
Structural/
Parameter
Mean/
Estimate
Structural/
Parameter
Mean/
Estimate
Days/supply/(P=0) α 371.356 α 388.956 α 331.509
Myopia β 0.321 β 0.394 β 0.303
Marginal/price/effect η H1.886 η H1.958 η H1.779
Deductible/effect Κdeduct H8.830 Κdeduct H9.113 Κdeduct H7.703
Stark/gap/effect Κstark H6.358 Κstark H5.801 Κstark H13.634
Implied/elasticity ε H0.117 ε H0.121 ε H0.109
Description
Structural/
Parameter
Mean/
Estimate
Structural/
Parameter
Mean/
Estimate
Structural/
Parameter
Mean/
Estimate
Days/supply/(P=0) α 390.579 α 359.010 α 476.529
Myopia β 0.377 β 0.469 β 0.509
Marginal/price/effect η H2.017 η H1.784 η H2.018
Deductible/effect Κdeduct H10.199 Κdeduct H12.813 Κdeduct H9.554
Stark/gap/effect Κstark H5.168 Κstark H12.454 Κstark H3.086
Implied/elasticity ε H0.117 ε H0.128 ε H0.115
Notes:/Authors'/calculations./Data/are/shown/only/for/individuals/within/the/1st/to/99th/percentiles/of/the/distribution/of/the/
predicted/trend/in/consumption;/individuals/too/dissimilar/from/the/regression/sample/in/this/dimension/are/dropped./All/parameters/
shown/are/averages/except/for/the/hyperbolic/discount/factor./Following/Goldman,/et/al./(2004),/chronic/illnesses/are/identified/using/
diagnosis/codes/from/the/individuals'/medical/claims/histories.
Full/Sample/[N=1,985,229]////// Chronic/(All)/[N=1,330,677] NonHChronic/[N=627,941]
Hypertension/[N=843,867]
Hypercholesterolemia/
[N=338,802] Diabetes/[N=308,165]
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